WO2020149993A1 - Infusing drug solution directly into brain fluid - Google Patents
Infusing drug solution directly into brain fluid Download PDFInfo
- Publication number
- WO2020149993A1 WO2020149993A1 PCT/US2019/068592 US2019068592W WO2020149993A1 WO 2020149993 A1 WO2020149993 A1 WO 2020149993A1 US 2019068592 W US2019068592 W US 2019068592W WO 2020149993 A1 WO2020149993 A1 WO 2020149993A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- infusion
- drug
- brain
- lumen
- patient
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 130
- 229940079593 drug Drugs 0.000 title claims abstract description 129
- 210000004556 brain Anatomy 0.000 title claims abstract description 115
- 239000012530 fluid Substances 0.000 title claims abstract description 83
- 238000001802 infusion Methods 0.000 claims abstract description 186
- 239000012669 liquid formulation Substances 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 206010015037 epilepsy Diseases 0.000 claims abstract description 16
- 229940126701 oral medication Drugs 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 238000007914 intraventricular administration Methods 0.000 claims description 46
- 238000005070 sampling Methods 0.000 claims description 40
- 208000012902 Nervous system disease Diseases 0.000 claims description 26
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 24
- 238000004891 communication Methods 0.000 claims description 15
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 10
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 10
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 8
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 8
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229960000604 valproic acid Drugs 0.000 claims description 8
- 239000001961 anticonvulsive agent Substances 0.000 claims description 7
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 6
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 claims description 6
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 claims description 5
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 5
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 5
- 229940102566 valproate Drugs 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 229960001403 clobazam Drugs 0.000 claims description 4
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 4
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 claims description 4
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 4
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims description 4
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims description 4
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims description 4
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 4
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 claims description 4
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 4
- PRMWGUBFXWROHD-UHFFFAOYSA-N perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 claims description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 4
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 4
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 4
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 4
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims description 4
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000007204 Brain death Diseases 0.000 claims description 3
- 208000018652 Closed Head injury Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000027520 Somatoform disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 230000006931 brain damage Effects 0.000 claims description 3
- 231100000874 brain damage Toxicity 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 229960000693 fosphenytoin Drugs 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 229960004391 lorazepam Drugs 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000027753 pain disease Diseases 0.000 claims description 3
- 229960001233 pregabalin Drugs 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 claims description 2
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 claims description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000571 acetazolamide Drugs 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 239000002582 adenosine A1 receptor agonist Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 229940075225 aptiom Drugs 0.000 claims description 2
- 229940072698 ativan Drugs 0.000 claims description 2
- 229940000221 banzel Drugs 0.000 claims description 2
- 229960002161 brivaracetam Drugs 0.000 claims description 2
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 claims description 2
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004064 bumetanide Drugs 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- 229940057922 carbatrol Drugs 0.000 claims description 2
- 229940029783 cerebyx Drugs 0.000 claims description 2
- 229960003120 clonazepam Drugs 0.000 claims description 2
- 229960004362 clorazepate Drugs 0.000 claims description 2
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 claims description 2
- 229940075922 depacon Drugs 0.000 claims description 2
- 229940089052 depakene Drugs 0.000 claims description 2
- 229940075925 depakote Drugs 0.000 claims description 2
- 229940074202 diastat Drugs 0.000 claims description 2
- 229960003529 diazepam Drugs 0.000 claims description 2
- 229940064790 dilantin Drugs 0.000 claims description 2
- 229940089063 epitol Drugs 0.000 claims description 2
- 229940051493 equetro Drugs 0.000 claims description 2
- 229960003233 eslicarbazepine acetate Drugs 0.000 claims description 2
- 229960002767 ethosuximide Drugs 0.000 claims description 2
- 229960003533 ethotoin Drugs 0.000 claims description 2
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003472 felbamate Drugs 0.000 claims description 2
- 229940099239 felbatol Drugs 0.000 claims description 2
- 229960001582 fenfluramine Drugs 0.000 claims description 2
- 229940024040 fycompa Drugs 0.000 claims description 2
- 229960002870 gabapentin Drugs 0.000 claims description 2
- TZDUHAJSIBHXDL-UHFFFAOYSA-N gabapentin enacarbil Chemical compound CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 TZDUHAJSIBHXDL-UHFFFAOYSA-N 0.000 claims description 2
- 229940084457 gabitril Drugs 0.000 claims description 2
- 229940015456 gralise Drugs 0.000 claims description 2
- 229940074066 horizant Drugs 0.000 claims description 2
- 229940062717 keppra Drugs 0.000 claims description 2
- 229940073092 klonopin Drugs 0.000 claims description 2
- 229960002623 lacosamide Drugs 0.000 claims description 2
- 229940072170 lamictal Drugs 0.000 claims description 2
- 229960001848 lamotrigine Drugs 0.000 claims description 2
- 229960004002 levetiracetam Drugs 0.000 claims description 2
- 229940009697 lyrica Drugs 0.000 claims description 2
- 229960000906 mephenytoin Drugs 0.000 claims description 2
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003729 mesuximide Drugs 0.000 claims description 2
- 229940090010 mysoline Drugs 0.000 claims description 2
- 229940072228 neurontin Drugs 0.000 claims description 2
- 229940044442 onfi Drugs 0.000 claims description 2
- 229960001816 oxcarbazepine Drugs 0.000 claims description 2
- 229940065847 oxtellar Drugs 0.000 claims description 2
- 229960005198 perampanel Drugs 0.000 claims description 2
- 229960002695 phenobarbital Drugs 0.000 claims description 2
- 229940052794 phenytek Drugs 0.000 claims description 2
- 229960002036 phenytoin Drugs 0.000 claims description 2
- 229940017430 potiga Drugs 0.000 claims description 2
- 229960002393 primidone Drugs 0.000 claims description 2
- 229960003312 retigabine Drugs 0.000 claims description 2
- 229960003014 rufinamide Drugs 0.000 claims description 2
- 229940106773 sabril Drugs 0.000 claims description 2
- 229940010817 stavzor Drugs 0.000 claims description 2
- 229940090016 tegretol Drugs 0.000 claims description 2
- 229960001918 tiagabine Drugs 0.000 claims description 2
- 229940035305 topamax Drugs 0.000 claims description 2
- 229940115663 topiragen Drugs 0.000 claims description 2
- 229960004394 topiramate Drugs 0.000 claims description 2
- 229940061414 trileptal Drugs 0.000 claims description 2
- 229960004453 trimethadione Drugs 0.000 claims description 2
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims description 2
- 229940072690 valium Drugs 0.000 claims description 2
- 229960005318 vigabatrin Drugs 0.000 claims description 2
- 229940089285 vimpat Drugs 0.000 claims description 2
- 229940063682 zarontin Drugs 0.000 claims description 2
- 229940061639 zonegran Drugs 0.000 claims description 2
- 229960002911 zonisamide Drugs 0.000 claims description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960002672 isocarboxazid Drugs 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229960001078 lithium Drugs 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 55
- 230000004043 responsiveness Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 39
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 33
- 238000010586 diagram Methods 0.000 description 23
- 230000004888 barrier function Effects 0.000 description 16
- 230000037361 pathway Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000013461 design Methods 0.000 description 15
- 239000000463 material Substances 0.000 description 14
- 230000009977 dual effect Effects 0.000 description 12
- 210000003140 lateral ventricle Anatomy 0.000 description 12
- 238000012864 cross contamination Methods 0.000 description 11
- 238000002513 implantation Methods 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000035515 penetration Effects 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 210000003625 skull Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 210000003703 cisterna magna Anatomy 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000000560 biocompatible material Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000002610 neuroimaging Methods 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 210000001638 cerebellum Anatomy 0.000 description 4
- 210000002987 choroid plexus Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 230000003556 anti-epileptic effect Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
- 240000007643 Phytolacca americana Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000012858 resilient material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005641 tunneling Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010070666 Cortical dysplasia Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010063629 Hippocampal sclerosis Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000037004 Myoclonic-astatic epilepsy Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000009136 Periventricular nodular heterotopia Diseases 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004959 anterior horn of lateral ventricle Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003096 cerebellopontine angle Anatomy 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000016313 myoclonic-astastic epilepsy Diseases 0.000 description 1
- 210000000103 occipital bone Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
- A61M5/14546—Front-loading type injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0693—Brain, cerebrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M27/006—Cerebrospinal drainage; Accessories therefor, e.g. valves
Definitions
- the present disclosure generally relates to intraventricular administration of drugs to the brain. More particularly, the disclosure generally relates to an intraventricular access device configurable to provide a slow and continuous infusion of a drug solution into cerebrospinal fluid.
- BBB blood-brain barrier
- trastuzumab a humanized IgG1 kappa monoclonal antibody for the treatment of metastatic breast cancer has a cerebrospinal fluid (CSF) level that is 300-fold lower than plasma levels when administered intravenously.
- CSF cerebrospinal fluid
- CED convection-enhanced delivery
- intra-arterial injection high dose systemic chemotherapy
- drug-loaded wafers that are inserted directly into the tumor resection cavity
- administration of drugs to the CSF include: convection-enhanced delivery (CED), intra-arterial injection, high dose systemic chemotherapy, drug-loaded wafers that are inserted directly into the tumor resection cavity, and administration of drugs to the CSF.
- Methods also exist to temporarily increase the permeability of the BBB and include the use of osmotic solutions (mannitol), pulsed ultrasound in combination with microbubbles, and radiation therapy.
- the Ommaya Reservoir is a type of device that allows for direct access to the CSF from a syringe or external pump without additional surgery at each drug administration.
- An external ventricular drain is another type of device that allows for access to the CSF, typically to drain excess CSF to relieve and reduce intracranial pressure (ICP).
- ICP intracranial pressure
- the Ommaya Reservoir is an intraventricular catheter system that allows for either sampling of cerebrospinal fluid or less commonly intermittent direct administration of drugs to the CSF. They were invented in 1963 and when used for chemotherapy are primarily used for the delivery of chemotherapy agents such as methotrexate or Ara-C to the CSF for patients with leptomeningeal disease and for continuous sampling of the CSF for potential infection, progression of CSF based cancers and occasionally for obtaining a drug level.
- chemotherapy agents such as methotrexate or Ara-C
- One example of such a reservoir is the IntegraTM Reservoir (Integra LifeSciences Corporation).
- AresTM Medtronic ventricular catheter has 32 flow holes with four lines of 8 holes spaced at 90o intervals– to limit clogging from ventricular contents though never a focus on brain drug delivery. These devices are never used for chronic brain drug delivery.
- CED catheters are designed to infuse drug directly into the targeted tissue.
- the barium- impregnated Medtronic® PS Medical (Goleta, CA, USA; Catalog number 43209) and Vygon US LLC (Valley Forge, PA, USA) are examples of devices that have been used in CED trials (Debinski and Tatter 2009).
- Infuseon Therapeutics (US Patents Nos. 8,808,234 and 8,979,822 which are incorporated by reference herein) is also developing a new catheter design for CED that allows for delivery of drugs to the brain via four independent flexible micro catheters.
- the device is designed for use over up to several days (but not for chronic use over weeks or months).
- the catheters are made from silicon and each microcatheter has a diameter of 0.38 mm.
- the main issue with CED catheters is backflow of the infusate during infusion and the lack of ability to use them for chronic infusion.
- the present invention relates to the direct administration of drug therapies to the brain through an intraventricular access device that allows for access to the CSF through a port located just beneath the scalp of a patient.
- the system can furthermore be attached to an implantable drug pump (e.g. Prometra® Programmable Pump by Flowonix Medical or the Synchromed® by Medtronic) or an external syringe or equivalent type pump.
- an implantable drug pump e.g. Prometra® Programmable Pump by Flowonix Medical or the Synchromed® by Medtronic
- an external syringe or equivalent type pump e.g. Prometra® Programmable Pump by Flowonix Medical or the Synchromed® by Medtronic
- An aspect of the invention is a method of treating a subject which may be a human by directly infusing a drug solution into the brain of the subject.
- the drug solution is infused from a catheter at a metered rate of 5ml per day or less, 4ml per day or less, or about 1ml per day ⁇ 50%.
- the drug in the solution may be any drug and includes antiepileptic drugs.
- the pump may be external or implanted into the subject. Infusion of the drug into the brain may be enhanced by the use of osmotic solutions including solutions of mannitol, pulse ultra sound in combination with microbubbles, and radiation therapy.
- the method may include extracting small amounts of fluid from the brain of about 3ml or less and testing the brain fluid for drug concentration and thereafter, adjusting the flow rate of the drug to obtain a desired therapeutic level.
- the methodology of the invention can be carried out to treat a range of patients, it may be focused on treating patients with epilepsy and in particular, treating patients with forms of epilepsy which are particularly difficult to treat.
- the method may be applied to treating patients who have not responded well to the treatment of epilepsy by the oral administration of drugs. Further, the patients treated may be patients diagnosed as being in danger of serious brain damage or death if the epilepsy from which they are suffering continues untreated.
- An aspect of the invention involves selecting a population of patients which are diagnosed as being substantially nonresponsive to treatment with oral anti-epileptic medications and in some cases, non-responsive to treatment via injection such as intramuscular or intravenous injections.
- the medication administered to the patient may be a medication which causes substantial adverse effects on other portions of the body and as such, is delivered directly to the brain in a manner so as to substantially avoid contacting other parts of the body or, at least, avoid contacting other organs in amounts sufficient to cause adverse effects on those organs.
- the patient is first diagnosed with a neurological disorder such as described herein which disorder may be epilepsy.
- a neurological disorder such as described herein which disorder may be epilepsy.
- the diagnosed patient is treated and found non-responsive to treatments by conventional administration such as oral administration of a drug and may further be diagnosed as having a life threatening neurological disorder.
- the patient is properly informed with respect to risks after which a catheter is inserted through the scalp and the skull of the patient wherein the catheter is comprised of an infusion lumen which delivers drug solution directly to the subject’s brain and an aspiration lumen which withdraws fluid from the subject’s brain.
- Solution is delivered to the subject’s brain at a relatively slow rate as described herein which may be 5, 4, 3, 2, 1 or even as low as 0.5 milliliter per day ⁇ 50%.
- the solution contains a drug, which may be an anti-epileptic drug at a concentration in a range of from 10mg/ml to 500 mg/ml.
- a drug which may be an anti-epileptic drug at a concentration in a range of from 10mg/ml to 500 mg/ml.
- Another aspect of the invention is a method of treatment wherein the patient is first diagnosed with epilepsy that is refractory to treatment; patients may have an abnormality related to hippocampal sclerosis, focal cortical dysplasia, periventricular heterotopias Dravet syndrome, Lennox-Gastaut syndrome, Doose syndrome, and West syndrome which may have a specific genetic cause.
- the diagnosed patient is treated and found non-responsive to treatments by conventional administration such as oral administration of a drug e.g. Valproate.
- the patient is diagnosed as having a serious form of the disease.
- the patient may be incapable of, or unwilling to take medication for a life threating condition.
- a catheter is inserted through the scalp and the skull of the patient wherein the catheter is comprised of an infusion lumen which delivers drug solution (e.g. Valproate) directly to the subject’s brain and an aspiration lumen which withdraws fluid from the subject’s brain.
- the catheters are attached to an implantable infusion pump system.
- a solution of Valproate at a concentration of 50 mg/ml to 450mg/ml is delivered to the subject’s brain at a relatively slow rate as described herein which may be one milliliter per day ⁇ 35%.
- fluid is withdrawn (the withdrawal of fluid takes less than 15 minutes) from the patient’s CSF Fluid containing areas (e.g.
- the lateral ventricle, third ventricle, cisterna magna, lumbar cistern or basilar skull cisterns using the aspiration lumen which is connected to a container.
- Responsiveness of the patient and the concentration of the drug found in the fluid aspirated from the patient’s brain is assayed and analyzed after which the rate of infusion or type of drug being infused may be changed.
- the rate is generally changed by increasing or decreasing the amount of drug by 10% to 30% per day and adjusting as needed based on patient responsiveness.
- the anti-epileptic medication is a medication selected from the group consisting of:
- Keppra levetiracetam
- Lamictal lamotrigine
- Lyrica pregabalin
- Zonegran (zonisamide);
- Adenosine a1 receptor agonists [0059] Adenosine a1 receptor agonists.
- the drug is valproic acid or a pharmaceutically acceptable salt thereof in a solution administered from either an external pump or a pump implanted into the subject and further wherein surfaces of the catheter are coated with biocompatible materials which inhibits cell adhesion and/or anti-microbial compounds which inhibit infection.
- the device and method of the invention can be employed to treat a wide range of different neurological diseases including post-traumatic stress disorder (PTSD) bipolar disorder, a range of different types of brain cancers, Alzheimer’s diseases, Parkinson’s diseases, closed head injury, stroke, multiple sclerosis, depression, schizophrenia, and anxiety.
- PTSD post-traumatic stress disorder
- the invention would more likely be employed in situations where the patient had been non- responsive to or completely non-compliant with oral medications and/or any type of available injectable medications including IV medication.
- the device and methodology of the invention could be applied to treat a wide range of patients and diseases it is particularly adapted to treat the patients selected for certain criteria. Those criteria include patients who have:
- a device may include an intraventricular access device.
- the intraventricular access device may include a catheter and a container.
- the catheter may include an aspiration lumen and an infusion lumen. A distal end of the catheter may be positionable, during use, in a subject’s brain.
- the container may be coupled to a proximal end of the aspiration lumen. The proximal end of the aspiration lumen may be in fluid communication with the container.
- the device inhibits cross contamination between a first fluid in the aspiration lumen and a second fluid in the infusion lumen.
- the container may include a barrier positioned between a proximal opening of the aspiration lumen and at least a portion of the infusion lumen adjacent to and/or associated with the container.
- the barrier may inhibit penetration of a surgical instrument.
- the container may include a marker to indicate a position of the barrier.
- the infusion lumen is positioned in the aspiration lumen or at least a portion of the aspiration lumen is positioned in the infusion lumen.
- the aspiration lumen and the infusion lumen may include two different lumens positioned adjacent one another.
- the aspiration lumen and the infusion lumen are different lengths when positioned, during use, in the subject’s brain such that a distal end of the aspiration lumen and a distal end of the infusion lumen are positioned a distance away from one another.
- a distal end of the aspiration lumen comprises a first opening and a distal end of the infusion lumen comprises a second opening.
- the first opening and the second opening may be directed in a substantially opposing directions to inhibit cross contamination of fluids.
- a distal end of the aspiration lumen and/or the infusion lumen comprises at least one opening or a plurality of openings which are inhibited from opening except when pressure is applied to the opening.
- At least a portion of the container is formed from material that is penetrable by a needle (e.g., a hypodermic needle) and substantially reseals after extraction of the needle.
- a needle e.g., a hypodermic needle
- At least portions of the device are formed from and/or coated in biocompatible materials which inhibit cell adhesion and/or comprises an antimicrobial.
- the infusion lumen may be coupled to a pump positioned externally or internally relative to the subject.
- a method includes aspirating and infusing at least a portion of a subject’s brain.
- the method may include penetrating an upper portion of a container of a device using a needle.
- the method may include aspirating a first fluid from a first portion of a subject’s brain through an aspiration lumen coupled to the container and using the needle.
- the method may include infusing a second fluid into a second portion of a subject’s brain through an infusion lumen coupled to the container and the aspiration lumen.
- the method may include inhibiting penetration of the infusion lumen by the needle.
- the method may include infusing the second fluid using a pump coupled to the infusion lumen, wherein the pump is positioned externally or internally relative to the subject.
- the method may include positioning at least a portion of the infusion lumen coupled to a pump subcutaneously.
- the method may include positioning at least a portion of the aspiration and/or the infusion lumen in the subject’s brain using a substantially inflexible stylet.
- the stylet may be positioned in the aspiration lumen by running the stylet through the container.
- the method may include observing at least a portion of the device during implantation using neuroimaging.
- the method may include inhibiting penetration of the infusion lumen by the needle using a barrier positioned between a proximal opening of the aspiration lumen and at least a portion of the infusion lumen adjacent to and/or associated with the container.
- the method may include inhibiting at least one opening at a distal end of the aspiration lumen and/or the infusion lumen from opening except when pressure is applied to the opening in a first direction.
- the method may include inhibiting the at least one opening in a second direction from opening even under pressure.
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the drug is a valproic acid or a pharmaceutically acceptable salt or base thereof.
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the drug is a pregabalin or a pharmaceutically acceptable salt or base thereof.
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the drug is a fosphenytoin or a pharmaceutically acceptable salt or base thereof.
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the drug is a lorazepam or a pharmaceutically acceptable salt or base thereof.
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the drug is a valproic acid or a pharmaceutically acceptable salt or base thereof, and the neurological disorder is epilepsy, and the use further includes:
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder
- the neurological disorder is epilepsy and the use further includes:
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is post-traumatic stress disorder (PTSD) and the use further includes: [00115] aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
- PTSD post-traumatic stress disorder
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder
- the neurological disorder is bipolar disorder and the use further includes:
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is brain cancer and the use further includes:
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is headache and the use further includes:
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is pain disorder and the use further includes:
- the invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
- a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid;
- a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
- a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is anxiety and the use further includes:
- FIG. 1 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a catheter design with a concentric dual lumen design.
- Infusion and sampling ports are implanted in one of the lateral ventricles.
- the infusion port (outer lumen) is connected to an implanted pump (not shown).
- FIG. 2 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a side by side dual lumen design including an infusion pathway distinct from the infusion catheter coming from the pump (not shown) which is shielded from the sampling port from being penetrated by a or other needle during aspiration.
- FIG. 3 depicts a diagram of a cross sectional view of an embodiment of an intraventricular access device implanted with the sampling and infusion ports located in one of the lateral ventricles.
- the infusion and sampling catheter in the brain is connected to a container which is in turn connected to an implantable pump that is located in the abdomen.
- FIG. 4 depicts a diagram of a cross sectional view of an embodiment of an intraventricular access device implanted with the sampling and infusion ports located in one of the lateral ventricles.
- the infusion and sampling catheter in the brain is connected to a container which is in turn connected to an external syringe pump.
- FIG. 5 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a side by side dual lumen design.
- the infusion and sampling ports are implanted in one of the lateral ventricles.
- a container fluidly coupled to at least the infusion lumen may allow for either directly injecting drugs into the container or directly to the ventricles, or to sampling CSF from the container or directly from patient using an external syringe (or an external pump).
- FIG. 6 depicts a diagram of a cross sectional view of an embodiment of an access device implanted with the sampling and infusion ports located over the cisterna magna and the cerebellum.
- the tip of the catheter can be directed to the cisterna magna, cisterns in the cerebellopontine angle, in the fourth ventricle or in the supra-cerebellar cistern direction.
- the infusion and sampling catheter in the brain is connected to a container which is in turn connected to an implantable pump that is located in the abdomen.
- FIG. 7 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a side by side dual lumen design.
- the infusion and sampling ports are implanted in one of the lateral ventricles.
- the infusion port (right lumen in illustrator) is connected to an implanted pump (not shown) located near the abdomen.
- FIGS. 8A-F depict diagrams of a cross sectional view of several embodiments of a various dual lumen catheters that may be used for the device described herein as well as one or more stylets positioned in one or more of the lumens.
- FIG. 9 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a side by side dual lumen design with multiple flow holes in the infusion catheter.
- the flow holes may be open or may each consist of small“slits” that open when drug is infused (when there is positive pressure) and close when drug is not infused.
- FIG.10 depicts a diagram of a top view a skull, and of an embodiment of a portion of an implanted intraventricular access device detailing an implantation method.
- FIG.11 depicts a diagram of a side view of a skull, and an embodiment of a portion of an implanted intraventricular access device detailing an implantation method.
- FIG. 12 depicts a diagram of a cross sectional view of an embodiment of a portion of an implanted intraventricular access device detailing an implantation method.
- first,”“second,”“third,” and so forth as used herein are used as labels for nouns that they precede, and do not imply any type of ordering (e.g., spatial, temporal, logical, etc.) unless such an ordering is otherwise explicitly indicated.
- a“third die electrically connected to the module substrate” does not preclude scenarios in which a“fourth die electrically connected to the module substrate” is connected prior to the third die, unless otherwise specified.
- a“second” feature does not require that a“first” feature be implemented prior to the“second” feature, unless otherwise specified.
- Various components may be described as“configured to” perform a task or tasks.
- “configured to” is a broad recitation generally meaning“having structure that” performs the task or tasks during operation.
- the component can be configured to perform the task even when the component is not currently performing that task (e.g., a set of electrical conductors may be configured to electrically connect a module to another module, even when the two modules are not connected).
- “configured to” may be a broad recitation of structure generally meaning“having circuitry that” performs the task or tasks during operation.
- the component can be configured to perform the task even when the component is not currently on.
- the circuitry that forms the structure corresponding to “configured to” may include hardware circuits.
- the term“catheter” as used herein generally refers to medical devices that can be inserted in the body to treat diseases or perform a surgical procedure.
- Coupled generally refers to pieces which may be used operatively with each other, or physically joined or physically linked together directly, with or without one or more intervening members.
- CSF sampling is inherently important both from a safety and efficacy perspective. From a safety perspective, the ability to both monitor potential infection as well as drug levels is important. From an efficacy perspective, understanding drug levels are important to monitor drug treatments. Accordingly, there is a desire to provide a device for the direct administration of drug therapies to the brain through an intraventricular access device that allows for access to the CSF through a port located just beneath the scalp of a patient.
- the system can furthermore be attached to an implantable drug pump or an external syringe or equivalent type pump.
- an intraventricular access device may provide an implantable drug delivery device that facilitates drug administration as well as sampling in the brain of a human patient.
- the access for drug sampling may occur at a separate location than the drug infusion to minimize cross contamination.
- Drug sampling may be performed with a sharp needle and as such the intraventricular access device includes protections such that the needle for sampling will not penetrate the infusion catheter. With such design safeguards, mixing and inaccuracies may be avoided.
- Both infusion and sampling access points within the brain are done relatively close to each other as such sampling and infusion may be accomplished in such a way to minimize cross contamination.
- the drug delivery device is adapted for implantation into a human subject and drug delivery to the CSF.
- the drug delivery device includes a support structure that may be accessed via skin puncture to sample the CSF.
- a device may include an intraventricular access device 100.
- FIG. 1 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device 100, specifically a catheter design with a concentric dual lumen design.
- Infusion and sampling ports are implanted in one of the lateral ventricles 200 of a subject’s brain 300.
- the infusion port (outer lumen) is connected to an implanted pump.
- the intraventricular access device may include a catheter 110 and a container 120.
- the catheter may include an aspiration lumen 110a and an infusion lumen 110b.
- a distal end of the catheter (e.g., 5-6 cm length) may be positionable, during use, in a subject’s brain.
- the container 120 may be coupled to a proximal end of the aspiration lumen 110a.
- the proximal end of the aspiration lumen may be in fluid communication with the container.
- the device inhibits cross contamination between a first fluid in the aspiration lumen and a second fluid in the infusion lumen. Cross contamination may be inhibited by using two separate lumens for sampling and infusion.
- the container 120 may include a barrier 130 positioned between a proximal opening of the aspiration lumen and at least a portion of the infusion lumen adjacent to and/or associated with the container.
- the barrier may inhibit penetration of a surgical instrument (e.g., hypodermic needle).
- a needle may be used to collect a sample from the container conveyed up through the aspiration lumen and the barrier may inhibit accidental puncture of the infusion lumen by the needle during the procedure.
- FIG.2 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device 100, specifically a side by side dual lumen design including an infusion pathway distinct from the infusion catheter coming from the pump which is shielded from the sampling port from being penetrated by a hypodermic or other needle during aspiration.
- the infusion side or segment and the infusion pathway will be covered by a barrier (e.g., metal or other hard plastic material (e.g. PEEK)) to limit the ability of a needle to penetrate and potentially cause a fenestration between the two sides.
- a barrier e.g., metal or other hard plastic material (e.g. PEEK)
- the top portion on the container may be a silicon-type material that can be punctured by a needle, but which re- seals after the needle is withdrawn.
- the container may have guide members 180 (e.g., be a cone-shape) so that the needle will be guided to the location of the sampling lumen 110a.
- the container may include a marker to indicate a position of the barrier.
- one or more portions of the intraventricular access device 100 may include a marker of some kind including, but not limited to, any portion of the device positionable within the subject.
- the device may include multiple individually distinguishable markers. Markers may be used to assess a position of one or more portions of the device during and/or after implantation in a subject. A portion of the implant may include none, one or multiple markers. Markers may provide radiographic opacity. Markers may be biocompatible. Markers may be of any size or shape.
- a system may have multiple markers with different shapes in order to more easily identify different portions of the system and/or an orientation of one or more portions of the device.
- one or more markers may be formed from gold or tantalum.
- the intraventricular access device may be designed to operate as part of a drug delivery system.
- the system includes a catheter that has distal openings in the CSF.
- the proximal side of the catheter is connected to a modified reservoir or container that may be accessed using, for example, a standard needle to draw CSF fluid from the distal end of the catheter to sample the CSF.
- the infusion lumen may be coupled to a pump positioned externally or internally relative to the subject.
- the container may contain a pathway for drug infusion and is connectable to a catheter which may connect to an implantable, programmable, refillable, drug pump.
- the pump may be implanted in the abdominal region of a patient.
- FIG. 3 depicts a diagram of a cross sectional view of an embodiment of an intraventricular access device 100 implanted with the sampling and infusion ports 110a-b located in one of the lateral ventricles 200.
- the infusion and sampling catheter in the brain is connected to a container 120 which is in turn connected to an implantable pump 140 (e.g., via an extension of the infusion lumen or an additional lumen 110c coupled to the infusion lumen) that is located, for example, in the abdomen.
- a drug pump may be connected to an external pump 150 in addition to or in the alternative to an implantable pump.
- FIG.4 depicts a diagram of a cross sectional view of an embodiment of an intraventricular access device 100 implanted with the sampling and infusion ports 110a-b located in one of the lateral ventricles 200.
- the infusion and sampling catheter in the brain is connected to a container 120 which is in turn connected to an external pump 150 (e.g., a syringe pump via an extension of the infusion lumen or an additional lumen 110c coupled to the infusion lumen).
- an external pump 150 e.g., a syringe pump via an extension of the infusion lumen or an additional lumen 110c coupled to the infusion lumen.
- implantable drug pumps such as the Synchromed® (Medtronic) or Prometra® (Flowonix) (or IP 2000V (Tricumed) or Siromedes (Tricumed)) that may be used for local and continuous infusion of drug therapies.
- These drug pumps are currently indicated for intrathecal drug delivery and have 20-40 mL refillable reservoirs; Tricumed reservoirs can go as high as 100 mL. They are indicated for the treatment of chronic, intractable pain, severe spasticity, and cancer.
- an external syringe type pump can be utilized.
- Syringe type pumps can include a pump like a Baxter 150XL.
- Morphine and Baclofen are both drugs that could be used as well as chemotherapies and other drugs for treatment of chronic and nonchronic diseases of the brain.
- aspiration lumen 110a may function as a sampling portal for obtaining a sample of a subject’s fluid.
- FIG. 5 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device 100, specifically a side by side dual lumen design.
- the infusion and sampling ports are implanted in one of the lateral ventricles.
- a container 120 fluidly coupled to at least the infusion lumen 110a may allow either directly inject drugs into the ventricles, or to sample CSF from the patient using an external syringe 160 (or an external pump 150).
- FIG. 6 depicts a diagram of a cross sectional view of an embodiment of an access device 100 implanted with the sampling and infusion ports located in the cisterna magna.
- the infusion and sampling catheter in the brain is connected to a container 120 which is in turn connected to an implantable pump 140 that is located in the abdomen.
- the lumens 110 inserted into a spinal canal and tunneled (e.g., using a guidewire).
- the container 120 (e.g., sampling reservoir) would either sit above the occipital bone, or the muscle layer of the lumbar spine or adjacent to the pump (e.g., in the abdomen or over the back).
- the device 100 may be coupled, during use, to an internal or an external pump.
- features described herein to prevent cross contamination e.g., a barrier
- features described herein may be utilized including wherein the ends of the lumens being separated by a distance (e.g., 5mm to 1cm).
- the container (e.g., sampling reservoir) may separate from the double lumens so that the lumens are joined but the container has been separated from the joint lumens.
- a T-shaped separation may be used in the tubing with one pathway from the T moving towards an aspiration reservoir and one pathway towards the infusion system.
- a T coupling 115 may be used in other embodiments disclosed herein.
- An installation stylet as described herein may be temporarily positioned in the infusion lumen or the aspiration lumen during placement in a subject.
- the device may be positioned using neuroimaging or other forms of intraoperative detection. Markers (e.g., metal portions of the device) may be used for neuroimaging (e.g., CT or MRI). Markers (e.g., a magnetic piece) may be used for intraoperative detection.
- installing the access device 100 may include positioning the lumens in a burr hole above the cerebellum on the left or right side.
- FIG. 6 depicts a diagram of a cross sectional view of an embodiment of an access device 100 implanted with the sampling and infusion ports located adjacent, behind or over the cerebellum 208.
- the infusion and sampling catheter in the brain is connected to a container 120 which is in turn connected to an implantable pump that is located in the abdomen.
- a small microinsertion device may be used to position the lumens of the device through a small opening of less than one centimeter such that the lumens go through the burr hole opening.
- the inserted lumens may be flat or shaped like a tubing with two different pathways in it.
- the infusion pathway may infuse durally towards the dura or towards the brainstem or medial or lateral.
- the aspiration pathway may positioned in an opposing direction to the infusion lumen, specifically such that the opening of the aspiration lumen is directed in an opposing direction to the opening of the infusion lumen.
- the openings may be facing the same direction.
- the pathway of placing the device may be determined by a CT scan or an MRI scan preoperatively. Scans may depict the subarachnoid cisterns and placement of the catheter in the cerebellum.
- the targets could be any of the CSF subarachnoid cisterns including the cisterna magna, supracerebellar cisterns, CPA cistern or anterior to the brain stem cisterns.
- a T-shaped separation 115 of the tubing as described herein may include one pathway directed towards an aspiration reservoir and one pathway directed towards an infusion system.
- a stylet as described herein may be placed in the infusion lumen (or the aspiration lumen) when positioning the device in the subject. This same approach could be used to position the device over the sylvian fissure or interhemisphernic cistern.
- Elements in common to both a supracerebellar device and a hemisphere design include positioning the lumens through a small opening.
- Other common elements may include using preoperative imaging as a positioning guide and potentially using intra operative imaging as a positioning guide using either magnetic pieces in the device to see location and shape or using intraoperative MRI or intraoperative CT scan during positioning of the device.
- Common elements may include having a shape so that it would be anchored to the skull outside the cranium, and/or a stylet to guide passageway.
- the container may include exterior adhesive means for coupling the container to an exterior surface of the cranium.
- the aspiration lumen and the infusion lumen are different lengths when positioned, during use, in the subject’s brain such that a distal end of the aspiration lumen and a distal end of the infusion lumen are positioned a distance away from one another.
- FIG. 7 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device 100, specifically a side by side dual lumen design.
- the infusion and sampling ports 110 are implanted in one of the lateral ventricles 200.
- the infusion port (110b) is connected to an implanted pump located near the abdomen. Positioning the distal ends of the aspiration and infusion lumens a distance away from one another may inhibit cross contamination of fluids.
- FIGS.8A-C depict diagrams of a cross sectional view of several embodiments of a various dual lumen catheters 110 that may be used for the device described herein.
- at least a portion of the infusion lumen is positioned in the aspiration lumen or at least a portion of the aspiration lumen is positioned in the infusion lumen (e.g., as depicted in FIGS. 1 and 8A).
- the aspiration lumen and the infusion lumen may include a single lumen divided into two different lumens with a wall or divider (e.g., as depicted in FIG. 8B).
- the aspiration lumen and the infusion lumen may include two different lumens positioned adjacent one another (e.g., as depicted in FIGS.5 and 8C).
- a distal end of the aspiration lumen comprises a first opening and a distal end of the infusion lumen comprises a second opening.
- the first opening and the second opening may be directed in a substantially opposing directions (e.g., at least orthogonally relative to one another) to inhibit cross contamination of fluids.
- the openings may be directed away from one another by bending (e.g., during fabrication and/or implantation) at least a portion of at least one of the distal ends of the aspiration and/or infusion lumen.
- a distal end of the aspiration lumen and/or the infusion lumen comprises at least one opening or a plurality of openings.
- a distal end of the aspiration lumen and/or the infusion lumen comprises at least one opening which is inhibited from opening except when pressure is applied to the opening.
- FIG.9 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device 100, specifically a side by side dual lumen design with multiple flow holes 170 in the infusion catheter 110b.
- the flow holes may be open or may each consist of small“slits” that open when drug is infused (when there is positive pressure) and close when drug is not infused. This may be accomplished using a number of different methods.
- the opening may include a slit cut into a substantially resilient materials which flexes when under pressure but returns to an original shape after the pressure subsides (the original shape being a substantially closed slit in the lumen).
- the opening may include a more traditional opening closed off with a hinged cover (e.g., the hinge may include a resilient material as described herein since traditional mechanical hinges may be difficult to manufacture at the current dimensions).
- At least a portion of the container is formed from material that is penetrable by a needle and substantially reseals after extraction of the needle.
- specialized needles may be employed that allow resealing and multiple penetrations when cerebrospinal fluid is aspirated.
- Specialized needles may include non-coring needles. For example a small non-coring butterfly needle may be used to (e.g., 23 or 25 gauge connected to a three-way tap) access the reservoir and collect a small amount of CSF.
- the portion of the container may be on a proximal portion at least in a relation to the aspiration lumen such that the portion is facing away from the subject and therefore accessible. At least a portion or all of the container may be positioned subcutaneously in the subject (e.g., between a subject’s skull and skin). The resealable portion of the container may be exposed through the skin of the patient or be positioned beneath the skin. The resealable portion of the container may be formed from silicon. The reasealable portion may include an opening with a recloseable cap or stopper. The resealable portion may be replaceable after implantation.
- At least portions of the device are formed from and/or coated in biocompatible materials which inhibit cell adhesion.
- biocompatible materials such as Pebax, HDPE, LDPE, PTFE (polytetrafluoroethylene), ePTFE (expanded polytetrafluoroethylene), and polyimide may be used to inhibit cell adhesion.
- PTFE polytetrafluoroethylene
- ePTFE expanded polytetrafluoroethylene
- polyimide polyimide
- mechanical smoothing may be used on portions to limit micro locations for adhesions and the shapes of the holes can be made slit-like or very small via manufacturing techniques such as laser micromachining.
- At least portions of the device are formed from and/or coated in biocompatible materials comprising an antimicrobial.
- Antibacterial coatings composed of either silver or antibiotic impregnation similar to the catheters currently on the market.
- Portions of the device may be impregnated with antibiotics (e.g., rifampicin and clindamycin).
- Choice of materials may be important as regards manufacture of devices described herein. For example, granuloma associated with morphine spine infusion has been of concern. Being careful of the molecule (morphine appears to be a major culprit), making sure the device materials in the infusion system are produced using high quality products to avoid impurities, and/or placing the catheter in areas of high CSF flow relative the flow in the spinal areas, may result in the risk for granulomas being minimized.
- the system can either be modular or in one continuous system.
- the catheter is in one system or can be in two pieces from the container.
- the container may be either preassembled with a top or with the top that can be added separately. If the top is in place, a modified spinal needle or another rigid type device is necessary for controlled placement. If it is in two pieces a standard cannula can be in place that is not sharp.
- general procedures of import may include long tunneling, antibiotic cuffs at entry sites, using filters, avoiding flushing, maintaining sterile techniques, sometimes using injected antibiotics and/or educating patients on self-care.
- FIGS. 9-11 depicts a diagram of a top view of an embodiment of a portion of an implanted intraventricular access device detailing an implantation method.
- insertion of devices described herein may include inserting extraventricular drains at Kocher’s point 190, to have the catheter tip in the frontal horn of the lateral ventricle.
- the catheter may be inserted on the right side of the brain via a frontal incision 192.
- the burr hole 194 may be created using a ventriculostomy procedure, sterile techniques, verification of catheter placement, tunneling 196 (including one or more incisions 198) and connections to drug pump.
- the catheter is designed to facilitate ease of use, accuracy, safety and durability of the procedure and the implant.
- a method includes aspirating and infusing at least a portion of a subject’s brain fluid.
- the method may include penetrating an upper portion of a container of a device using a needle.
- the method may include aspirating a first fluid from a first portion of a subject’s brain fluid through an aspiration lumen coupled to the container and using the needle.
- the method may include infusing a second fluid into a second portion of a subject’s brain fluid through an infusion lumen coupled to the container and the aspiration lumen.
- the method may include inhibiting penetration of the infusion lumen by the needle.
- the method may include infusing the second fluid using a pump coupled to the infusion lumen.
- the pump may be positioned externally or internally (e.g., subcutaneously, in a body cavity, etc.) relative to the subject.
- the method may include positioning at least a portion of the infusion lumen coupled to a pump subcutaneously.
- the method may include positioning at least a portion of the aspiration and/or the infusion lumen in the subject’s brain using a substantially inflexible stylet.
- the stylet may be positioned in the aspiration lumen by running the stylet through the container.
- FIGS.8D-F depict a stylet 115 positioned in one or more lumens during installation of the device described herein.
- the stylet 115 may be used to insert the device in a subject’s brain fluid.
- the stylet may be positioned in the aspiration and/or the infusion lumen.
- the stylet may be more than about 7 cms in length.
- the stylet may penetrate at least 1 ⁇ 2 the length of the aspiration catheter within the brain during use.
- the method may include observing at least a portion of the device during implantation using neuroimaging (e.g., MRI). Towards that end many if not all of the materials used to form the device may be compatible with common neuroimaging devices such as MRI.
- neuroimaging e.g., MRI
- a stylet may be used to assist insertion of the device by positioning the stylet in the aspiration lumen before the reservoir or through the reservoir for aspiration.
- a stylet may be used to assist insertion of the device by positioning the stylet in the infusion lumen before connection to an implantable or external pump.
- the method may include inhibiting penetration of the infusion lumen by the needle using a barrier positioned between a proximal opening of the aspiration lumen and at least a portion of the infusion lumen adjacent to and/or associated with the container. The barrier may inhibit cross contamination in general between the lumens.
- the barrier may be formed from the same materials as the container but may consist of a greater thickness (this may tactically alert a care giver inserting a needle that they are unknowingly inserting the needle to far into the container and close to penetrating the barrier.
- the barrier may be formed from a different material than the container.
- the barrier may be formed from a substantially rigid, rigid, or inflexible material such as PTFE or a metal or metal composite.
- the method may include inhibiting at least one opening at a distal end of the aspiration lumen and/or the infusion lumen from allowing fluids through the opening except when at least predetermined amount of pressure is applied to the opening in a first direction.
- the method may include inhibiting the opening from allowing fluids through the opening in a second direction even under pressure.
- Steps in inserting this specialized catheter Preparation: Standard bur hole, Dura will be coagulated and pia arachnoid opened. Assembly: Step one is aspirate csf, step two is flush infusion port, step three is check tubing from the pump and make sure there is a fluid head at top of tubing, step four connect infusion tubing to the housing, step five put a ligature, sow it up.
- Stylet position in sampling catheter must be such that putting in the stylet cannot poke the infusion catheter along its course by either:
- Housing has a pathway for the infusion catheter from the side and out the bottom central, on the side infusion pathway will snap onto the infusion catheter which can be modified for all infusion catheters
- Housing will be v shaped on inside for CSF collection
- Infusion port will have a to have a small 2 ml syringe with small tubing which can hook and flush it out the infusion tubing first to confirm debris has not clogged this tubing at time of placement of catheter.
- Volume for aspiration in the infusion can be 1.5– 2.5 mls of the V area in the housing for CSF aspiration and we want the volume small certainly don’t want it 5 mls like an ommaya.
- the infusion catheter internal diameter can be a smaller width than the aspiration width
- Two catheters will be coated toether on outside– shape is like a larger catheter in the middle which is the aspiration and a smaller one next to it which is than overlayed with a rubber so that it is one piece and one length when inserted.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method of treating a subject which may be a human suffering from epilepsy which may be a form of epilepsy resistant to treatment and particular patients which are resistant to treatment with oral medication. The method involves positioning a catheter device in the subject's brain and infusing a liquid formulation of a drug into a portion of the subject's brain through an infusion lumen at a rate of 5, 4, 3, 2, or 1 ml or less per day ±50%. The infusion may be constant and corrected by aspirating fluid from the patient's brain and testing the aspirated fluid for drug concentration. The rate of infusion by the formulation and the concentration of drug may be adjusted based on patient responsiveness.
Description
INFUSING DRUG SOLUTION DIRECTLY INTO BRAIN FLUID BACKGROUND OF THE INVENTION
1. Field of the Invention
[0001] The present disclosure generally relates to intraventricular administration of drugs to the brain. More particularly, the disclosure generally relates to an intraventricular access device configurable to provide a slow and continuous infusion of a drug solution into cerebrospinal fluid.
2. Background
[0002] One of the principle reasons for directly administering drug therapies to the brain is because the blood-brain barrier (BBB) limits that passage of nearly all large molecule and the majority of small molecule drugs (<500 Da) to the brain parenchyma. Since the BBB limits the penetration of drugs from the vasculature to the brain tissue, most drugs that are administered orally or by intravenous infusion do not reach sufficient concentrations in the brain parenchyma to have therapeutic effects. In addition, drugs that may have the highest potential efficacy against cancerous tissue are unable to reach the target tissue. For example, trastuzumab, a humanized IgG1 kappa monoclonal antibody for the treatment of metastatic breast cancer has a cerebrospinal fluid (CSF) level that is 300-fold lower than plasma levels when administered intravenously.
[0003] Several methods have been proposed to bypass the BBB to increase drug concentrations in the brain. These include methods for altering the administration of drugs for brain delivery including: convection-enhanced delivery (CED), intra-arterial injection, high dose systemic chemotherapy, drug-loaded wafers that are inserted directly into the tumor resection cavity, and administration of drugs to the CSF.
[0004] Methods also exist to temporarily increase the permeability of the BBB and include the use of osmotic solutions (mannitol), pulsed ultrasound in combination with microbubbles, and radiation therapy.
[0005] One method for direct administration of drugs to bypass the BBB is the use of an ommaya reservoir, which is described below. The Ommaya Reservoir is a type of device that allows for direct access to the CSF from a syringe or external pump without additional surgery at each drug administration. An external ventricular drain is another type of device that allows for access to the CSF, typically to drain excess CSF to relieve and reduce intracranial pressure (ICP).
[0006] The Ommaya Reservoir is an intraventricular catheter system that allows for either sampling of cerebrospinal fluid or less commonly intermittent direct administration of drugs to
the CSF. They were invented in 1963 and when used for chemotherapy are primarily used for the delivery of chemotherapy agents such as methotrexate or Ara-C to the CSF for patients with leptomeningeal disease and for continuous sampling of the CSF for potential infection, progression of CSF based cancers and occasionally for obtaining a drug level. One example of such a reservoir is the Integra™ Reservoir (Integra LifeSciences Corporation).
[0007] Several types of external ventricular drains exist to provide access to the CSF. These types of catheters are classified as Class 2 medical devices by the FDA. They may have an antibacterial coating to limit infection, which can occur in up to 25% of catheter placements in the brain. For example, the Ares™ Antibiotic Impregnated Catheter (Medtronic) and Bactiseal® (Codman Neuro, DePuySynthes, Johnson & Johnson) are impregnated with rifampicin and clindamycin and prevent bacterial colonization on all surfaces for up to 28 days. Other antibiotics such as minocycline/rifampin or silver may also be used to coat the device to limit infection. They may also contain barium impregnation for visualization on X-ray to verify proper positioning of the device within the brain.
[0008] Drug Infusion into the lumbar spine CSF via implantable catheters exist. These catheters infuse drug into a small space with small flow volumes which is because the space required for infusion is small. The size of the holes tends to be small.
[0009] In terms of brain catheters currently used for drainage, an example is the Ares™ (Medtronic) ventricular catheter has 32 flow holes with four lines of 8 holes spaced at 90º intervals– to limit clogging from ventricular contents though never a focus on brain drug delivery. These devices are never used for chronic brain drug delivery.
[0010] Catheters designed for convection enhanced delivery (CED) have been developed. CED catheters are designed to infuse drug directly into the targeted tissue. The barium- impregnated Medtronic® PS Medical (Goleta, CA, USA; Catalog number 43209) and Vygon US LLC (Valley Forge, PA, USA) are examples of devices that have been used in CED trials (Debinski and Tatter 2009). Infuseon Therapeutics (US Patents Nos. 8,808,234 and 8,979,822 which are incorporated by reference herein) is also developing a new catheter design for CED that allows for delivery of drugs to the brain via four independent flexible micro catheters. The device is designed for use over up to several days (but not for chronic use over weeks or months). The catheters are made from silicon and each microcatheter has a diameter of 0.38 mm. The main issue with CED catheters is backflow of the infusate during infusion and the lack of ability to use them for chronic infusion.
[0011] There are known complications beyond intracranial hemorrhage of brain drains which are external to the body and placed most commonly in cases of brain trauma, subarachnoid
hemorrhage or post neurosurgical. Infection is one of the most common types of complications associated with such devices. A common practice aimed at reducing this is to administer intravenous antibiotics to cover common skin flora for the duration of EVD placement. Though this appears to carry some benefit, it may contribute to the development of resistant organisms. Antibiotic-impregnated and ionized silver particle coated EVD catheters offer a similar level of protection compared with prophylactic intravenous antibiotics but come at a cost. Other strategies include sampling an EVD only when infection is suspected, monitoring EVD dressing site for drainage suggestive of CSF leak, maintaining collection system in the upright position, and not routinely changing drain tubing. In the setting of infection, it is common consensus that the colonized EVD catheter be removed and replaced with a new catheter, preferentially at a new site. Minimizing infection is a requirement for longer term placement.
[0012] The present invention relates to the direct administration of drug therapies to the brain through an intraventricular access device that allows for access to the CSF through a port located just beneath the scalp of a patient. The system can furthermore be attached to an implantable drug pump (e.g. Prometra® Programmable Pump by Flowonix Medical or the Synchromed® by Medtronic) or an external syringe or equivalent type pump.
[0013] Accordingly, there is a desire to provide a device for the direct administration of drug therapies to the brain through an intraventricular access device that allows for access to the CSF through a port located just beneath the scalp of a patient.
SUMMARY
[0014] An aspect of the invention is a method of treating a subject which may be a human by directly infusing a drug solution into the brain of the subject. The drug solution is infused from a catheter at a metered rate of 5ml per day or less, 4ml per day or less, or about 1ml per day ±50%. The drug in the solution may be any drug and includes antiepileptic drugs. The pump may be external or implanted into the subject. Infusion of the drug into the brain may be enhanced by the use of osmotic solutions including solutions of mannitol, pulse ultra sound in combination with microbubbles, and radiation therapy.
[0015] The method may include extracting small amounts of fluid from the brain of about 3ml or less and testing the brain fluid for drug concentration and thereafter, adjusting the flow rate of the drug to obtain a desired therapeutic level.
[0016] Although the methodology of the invention can be carried out to treat a range of patients, it may be focused on treating patients with epilepsy and in particular, treating patients with forms of epilepsy which are particularly difficult to treat. The method may be applied to treating patients who have not responded well to the treatment of epilepsy by the oral administration of drugs. Further, the patients treated may be patients diagnosed as being in danger of serious brain damage or death if the epilepsy from which they are suffering continues untreated.
[0017] An aspect of the invention involves selecting a population of patients which are diagnosed as being substantially nonresponsive to treatment with oral anti-epileptic medications and in some cases, non-responsive to treatment via injection such as intramuscular or intravenous injections.
[0018] In another aspect of the invention, the medication administered to the patient may be a medication which causes substantial adverse effects on other portions of the body and as such, is delivered directly to the brain in a manner so as to substantially avoid contacting other parts of the body or, at least, avoid contacting other organs in amounts sufficient to cause adverse effects on those organs.
[0019] In an aspect of the invention, the patient is first diagnosed with a neurological disorder such as described herein which disorder may be epilepsy. The diagnosed patient is treated and found non-responsive to treatments by conventional administration such as oral administration of a drug and may further be diagnosed as having a life threatening neurological disorder. The patient is properly informed with respect to risks after which a catheter is inserted through the scalp and the skull of the patient wherein the catheter is comprised of an infusion lumen which delivers drug solution directly to the subject’s brain and an aspiration lumen which
withdraws fluid from the subject’s brain. Solution is delivered to the subject’s brain at a relatively slow rate as described herein which may be 5, 4, 3, 2, 1 or even as low as 0.5 milliliter per day ±50%. The solution contains a drug, which may be an anti-epileptic drug at a concentration in a range of from 10mg/ml to 500 mg/ml. During the administration of the solution over a period of days, fluid is withdrawn from the patient’s brain using the aspiration lumen which is connected to a container. Responsiveness of the patient and the concentration of the drug found in the fluid aspirated from the patient’s brain is assayed and analyzed after which the rate of infusion or type of drug being infused may be changed.
[0020] Another aspect of the invention is a method of treatment wherein the patient is first diagnosed with epilepsy that is refractory to treatment; patients may have an abnormality related to hippocampal sclerosis, focal cortical dysplasia, periventricular heterotopias Dravet syndrome, Lennox-Gastaut syndrome, Doose syndrome, and West syndrome which may have a specific genetic cause. The diagnosed patient is treated and found non-responsive to treatments by conventional administration such as oral administration of a drug e.g. Valproate. The patient is diagnosed as having a serious form of the disease. The patient may be incapable of, or unwilling to take medication for a life threating condition. The patient is properly informed with respect to risks after which a catheter is inserted through the scalp and the skull of the patient wherein the catheter is comprised of an infusion lumen which delivers drug solution (e.g. Valproate) directly to the subject’s brain and an aspiration lumen which withdraws fluid from the subject’s brain. The catheters are attached to an implantable infusion pump system. A solution of Valproate at a concentration of 50 mg/ml to 450mg/ml is delivered to the subject’s brain at a relatively slow rate as described herein which may be one milliliter per day ±35%. During the administration of the solution over a period of days, fluid is withdrawn (the withdrawal of fluid takes less than 15 minutes) from the patient’s CSF Fluid containing areas (e.g. the lateral ventricle, third ventricle, cisterna magna, lumbar cistern or basilar skull cisterns) using the aspiration lumen which is connected to a container. Responsiveness of the patient and the concentration of the drug found in the fluid aspirated from the patient’s brain is assayed and analyzed after which the rate of infusion or type of drug being infused may be changed. The rate is generally changed by increasing or decreasing the amount of drug by 10% to 30% per day and adjusting as needed based on patient responsiveness.
[0021]
[0022] In another aspect of the invention, the anti-epileptic medication is a medication selected from the group consisting of:
[0023] Carbatrol, Epitol, Equetro, Tegretol (carbamazepine);
[0024] Gabitril (tiagabine);
[0025] Keppra (levetiracetam);
[0026] Lamictal (lamotrigine);
[0027] Lyrica (pregabalin);
[0028] Fenfluramine;
[0029] Gralise, Horizant, Neurontin, Gabarone (gabapentin);
[0030] Dilantin, Prompt, Di-Phen, Epanutin, Phenytek (phenytoin);
[0031] Topamax, Qudexy XR, Trokendi XR, Topiragen (topiramate);
[0032] Trileptal, Oxtellar (oxcarbazepine);
[0033] Depacon, Depakene, Depakote, Stavzor (valproate, valproic acid);
[0034] Zonegran (zonisamide);
[0035] Fycompa (perampanel);
[0036] Aptiom (eslicarbazepine acetate);
[0037] Vimpat (lacosamide);
[0038] Sabril (vigabatrin);
[0039] Banzel, Inovelon (rufinamide);
[0040] Cerebyx (fosphenytoin);
[0041] Zarontin (ethosuximide);
[0042] Solfoton, Luminal (phenobarbital);
[0043] Valium, Diastat (diazepam);
[0044] Ativan (lorazepam);
[0045] Lonopin, Klonopin (clonazepam);
[0046] Frisium, Onfi (clobazam);
[0047] Potiga (ezogabine);
[0048] Felbatol (felbamate);
[0049] Mysoline (primidone);
[0050] Acetazolamide;
[0051] Brivaracetam;
[0052] Clorazepate;
[0053] Ethotoin;
[0054] Mephenytoin;
[0055] Methsuximide;
[0056] Trimethadione;
[0057] Bumetanide;
[0058] Adenosine; and
[0059] Adenosine a1 receptor agonists.
[0060] In another aspect of the invention, the drug is valproic acid or a pharmaceutically acceptable salt thereof in a solution administered from either an external pump or a pump implanted into the subject and further wherein surfaces of the catheter are coated with biocompatible materials which inhibits cell adhesion and/or anti-microbial compounds which inhibit infection.
[0061] The device and method of the invention can be employed to treat a wide range of different neurological diseases including post-traumatic stress disorder (PTSD) bipolar disorder, a range of different types of brain cancers, Alzheimer’s diseases, Parkinson’s diseases, closed head injury, stroke, multiple sclerosis, depression, schizophrenia, and anxiety. In each case, the invention would more likely be employed in situations where the patient had been non- responsive to or completely non-compliant with oral medications and/or any type of available injectable medications including IV medication.
[0062] Although the device and methodology of the invention could be applied to treat a wide range of patients and diseases it is particularly adapted to treat the patients selected for certain criteria. Those criteria include patients who have:
[0063] (1) epilepsy;
[0064] (2) a form of epilepsy resistant to treatment;
[0065] (3) have been found resistant to treatment with oral medications including oral anti- epileptic medications;
[0066] (4) patients in danger of severe brain damage or death if seizures are not treated; and
[0067] (5) patients requiring very constant blood level of a drug in the brain to obtain appropriate treatment.
[0068] In some embodiments, a device may include an intraventricular access device. The intraventricular access device may include a catheter and a container. In some embodiments, the catheter may include an aspiration lumen and an infusion lumen. A distal end of the catheter may be positionable, during use, in a subject’s brain. In some embodiments, the container may be coupled to a proximal end of the aspiration lumen. The proximal end of the aspiration lumen may be in fluid communication with the container. In some embodiments, the device inhibits cross contamination between a first fluid in the aspiration lumen and a second fluid in the infusion lumen. In some embodiments, the container may include a barrier positioned between a proximal opening of the aspiration lumen and at least a portion of the infusion lumen adjacent to
and/or associated with the container. The barrier may inhibit penetration of a surgical instrument. The container may include a marker to indicate a position of the barrier.
[0069] In some embodiments, at least a portion of the infusion lumen is positioned in the aspiration lumen or at least a portion of the aspiration lumen is positioned in the infusion lumen. In some embodiments, the aspiration lumen and the infusion lumen may include two different lumens positioned adjacent one another.
[0070] In some embodiments, the aspiration lumen and the infusion lumen are different lengths when positioned, during use, in the subject’s brain such that a distal end of the aspiration lumen and a distal end of the infusion lumen are positioned a distance away from one another.
[0071] In some embodiments, a distal end of the aspiration lumen comprises a first opening and a distal end of the infusion lumen comprises a second opening. The first opening and the second opening may be directed in a substantially opposing directions to inhibit cross contamination of fluids.
[0072] In some embodiments, a distal end of the aspiration lumen and/or the infusion lumen comprises at least one opening or a plurality of openings which are inhibited from opening except when pressure is applied to the opening.
[0073] In some embodiments, at least a portion of the container is formed from material that is penetrable by a needle (e.g., a hypodermic needle) and substantially reseals after extraction of the needle.
[0074] In some embodiments, at least portions of the device are formed from and/or coated in biocompatible materials which inhibit cell adhesion and/or comprises an antimicrobial.
[0075] In some embodiments, the infusion lumen may be coupled to a pump positioned externally or internally relative to the subject.
[0076] In some embodiments, a method includes aspirating and infusing at least a portion of a subject’s brain. The method may include penetrating an upper portion of a container of a device using a needle. The method may include aspirating a first fluid from a first portion of a subject’s brain through an aspiration lumen coupled to the container and using the needle. The method may include infusing a second fluid into a second portion of a subject’s brain through an infusion lumen coupled to the container and the aspiration lumen. The method may include inhibiting penetration of the infusion lumen by the needle.
[0077] In some embodiments, the method may include infusing the second fluid using a pump coupled to the infusion lumen, wherein the pump is positioned externally or internally relative to the subject. The method may include positioning at least a portion of the infusion lumen coupled to a pump subcutaneously.
[0078] In some embodiments, the method may include positioning at least a portion of the aspiration and/or the infusion lumen in the subject’s brain using a substantially inflexible stylet. The stylet may be positioned in the aspiration lumen by running the stylet through the container. The method may include observing at least a portion of the device during implantation using neuroimaging.
[0079] In some embodiments, the method may include inhibiting penetration of the infusion lumen by the needle using a barrier positioned between a proximal opening of the aspiration lumen and at least a portion of the infusion lumen adjacent to and/or associated with the container.
[0080] In some embodiments, the method may include inhibiting at least one opening at a distal end of the aspiration lumen and/or the infusion lumen from opening except when pressure is applied to the opening in a first direction. The method may include inhibiting the at least one opening in a second direction from opening even under pressure.
[0081] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[0082] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[0083] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[0084] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the drug is a valproic acid or a pharmaceutically acceptable salt or base thereof.
[0085] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[0086] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[0087] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[0088] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a
neurological disorder, wherein the drug is a pregabalin or a pharmaceutically acceptable salt or base thereof.
[0089] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[0090] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[0091] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[0092] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the drug is a fosphenytoin or a pharmaceutically acceptable salt or base thereof.
[0093] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[0094] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[0095] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[0096] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the drug is a lorazepam or a pharmaceutically acceptable salt or base thereof.
[0097] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[0098] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[0099] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[00100] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a
neurological disorder, wherein the drug is a valproic acid or a pharmaceutically acceptable salt or base thereof, and the neurological disorder is epilepsy, and the use further includes:
[00101] aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
[00102] determining drug level in the sample; and
[00103] adjusting the rate of infusion of the liquid formulation based on the determined drug level in the sample fluid.
[00104] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[00105] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[00106] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[00107] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is epilepsy and the use further includes:
[00108] aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
[00109] determining drug level in the sample; and
[00110] adjusting the rate of infusion of the liquid formulation based on the determined drug level in the sample fluid.
[00111] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[00112] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[00113] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[00114] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is post-traumatic stress disorder (PTSD) and the use further includes:
[00115] aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
[00116] determining drug level in the sample; and
[00117] adjusting the rate of infusion of the liquid formulation based on the determined drug level in the sample fluid.
[00118] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[00119] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[00120] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[00121] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is bipolar disorder and the use further includes:
[00122] aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
[00123] determining drug level in the sample; and
[00124] adjusting the rate of infusion of the liquid formulation based on the determined drug level in the sample fluid.
[00125] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[00126] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[00127] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[00128] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is brain cancer and the use further includes:
[00129] aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
[00130] determining drug level in the sample; and
[00131] adjusting the rate of infusion of the liquid formulation based on the determined drug level in the sample fluid.
[00132] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[00133] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[00134] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[00135] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is headache and the use further includes:
[00136] aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
[00137] determining drug level in the sample; and
[00138] adjusting the rate of infusion of the liquid formulation based on the determined drug level in the sample fluid.
[00139] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[00140] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[00141] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[00142] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is pain disorder and the use further includes:
[00143] aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
[00144] determining drug level in the sample; and
[00145] adjusting the rate of infusion of the liquid formulation based on the determined drug level in the sample fluid.
[00146] The invention includes a use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
[00147] a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
[00148] a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
[00149] wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder, wherein the neurological disorder is anxiety and the use further includes:
[00150] aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
[00151] determining drug level in the sample; and
[00152] adjusting the rate of infusion of the liquid formulation based on the determined drug level in the sample fluid. BRIEF DESCRIPTION OF THE DRAWINGS
[00153] Advantages of the present invention may become apparent to those skilled in the art with the benefit of the following detailed description of the preferred embodiments and upon reference to the accompanying drawings.
[00154] FIG. 1 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a catheter design with a concentric dual lumen design. Infusion and sampling ports are implanted in one of the lateral ventricles. The infusion port (outer lumen) is connected to an implanted pump (not shown).
[00155] FIG. 2 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a side by side dual lumen design including an infusion pathway distinct from the infusion catheter coming from the pump (not shown) which is shielded from the sampling port from being penetrated by a or other needle during aspiration.
[00156] FIG. 3 depicts a diagram of a cross sectional view of an embodiment of an intraventricular access device implanted with the sampling and infusion ports located in one of the lateral ventricles. The infusion and sampling catheter in the brain is connected to a container which is in turn connected to an implantable pump that is located in the abdomen.
[00157] FIG. 4 depicts a diagram of a cross sectional view of an embodiment of an intraventricular access device implanted with the sampling and infusion ports located in one of
the lateral ventricles. The infusion and sampling catheter in the brain is connected to a container which is in turn connected to an external syringe pump.
[00158] FIG. 5 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a side by side dual lumen design. The infusion and sampling ports are implanted in one of the lateral ventricles. A container fluidly coupled to at least the infusion lumen may allow for either directly injecting drugs into the container or directly to the ventricles, or to sampling CSF from the container or directly from patient using an external syringe (or an external pump).
[00159] FIG. 6 depicts a diagram of a cross sectional view of an embodiment of an access device implanted with the sampling and infusion ports located over the cisterna magna and the cerebellum. The tip of the catheter can be directed to the cisterna magna, cisterns in the cerebellopontine angle, in the fourth ventricle or in the supra-cerebellar cistern direction. The infusion and sampling catheter in the brain is connected to a container which is in turn connected to an implantable pump that is located in the abdomen.
[00160] FIG. 7 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a side by side dual lumen design. The infusion and sampling ports are implanted in one of the lateral ventricles. The infusion port (right lumen in illustrator) is connected to an implanted pump (not shown) located near the abdomen.
[00161] FIGS. 8A-F depict diagrams of a cross sectional view of several embodiments of a various dual lumen catheters that may be used for the device described herein as well as one or more stylets positioned in one or more of the lumens.
[00162] FIG. 9 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device, specifically a side by side dual lumen design with multiple flow holes in the infusion catheter. The flow holes may be open or may each consist of small“slits” that open when drug is infused (when there is positive pressure) and close when drug is not infused.
[00163] FIG.10 depicts a diagram of a top view a skull, and of an embodiment of a portion of an implanted intraventricular access device detailing an implantation method.
[00164] FIG.11 depicts a diagram of a side view of a skull, and an embodiment of a portion of an implanted intraventricular access device detailing an implantation method.
[00165] FIG. 12 depicts a diagram of a cross sectional view of an embodiment of a portion of an implanted intraventricular access device detailing an implantation method.
[00166] While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof are shown by way of example in the drawings and may herein be
described in detail. The drawings may not be to scale. It should be understood, however, that the drawings and detailed description thereto are not intended to limit the invention to the particular form disclosed, but on the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the present invention as defined by the appended claims.
[00167] The headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description. As used throughout this application, the word "may" is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must). The words“include,”“including,” and“includes” indicate open-ended relationships and therefore mean including, but not limited to. Similarly, the words“have,” “having,” and“has” also indicated open-ended relationships, and thus mean having, but not limited to. The terms“first,”“second,”“third,” and so forth as used herein are used as labels for nouns that they precede, and do not imply any type of ordering (e.g., spatial, temporal, logical, etc.) unless such an ordering is otherwise explicitly indicated. For example, a“third die electrically connected to the module substrate” does not preclude scenarios in which a“fourth die electrically connected to the module substrate” is connected prior to the third die, unless otherwise specified. Similarly, a“second” feature does not require that a“first” feature be implemented prior to the“second” feature, unless otherwise specified.
[00168] Various components may be described as“configured to” perform a task or tasks. In such contexts,“configured to” is a broad recitation generally meaning“having structure that” performs the task or tasks during operation. As such, the component can be configured to perform the task even when the component is not currently performing that task (e.g., a set of electrical conductors may be configured to electrically connect a module to another module, even when the two modules are not connected). In some contexts,“configured to” may be a broad recitation of structure generally meaning“having circuitry that” performs the task or tasks during operation. As such, the component can be configured to perform the task even when the component is not currently on. In general, the circuitry that forms the structure corresponding to “configured to” may include hardware circuits.
[00169] Various components may be described as performing a task or tasks, for convenience in the description. Such descriptions should be interpreted as including the phrase“configured to.” Reciting a component that is configured to perform one or more tasks is expressly intended not to invoke 35 U.S.C. § 112 paragraph (f), interpretation for that component.
[00170] The scope of the present disclosure includes any feature or combination of features disclosed herein (either explicitly or implicitly), or any generalization thereof, whether or not it
mitigates any or all of the problems addressed herein. Accordingly, new claims may be formulated during prosecution of this application (or an application claiming priority thereto) to any such combination of features. In particular, with reference to the appended claims, features from dependent claims may be combined with those of the independent claims and features from respective independent claims may be combined in any appropriate manner and not merely in the specific combinations enumerated in the appended claims.
[00171] It is to be understood the present invention is not limited to particular devices or biological systems, which may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms“a”,“an”, and“the” include singular and plural referents unless the content clearly dictates otherwise. Thus, for example, reference to“a linker” includes one or more linkers. DETAILED DESCRIPTION DEFINITIONS
[00172] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
[00173] The term“catheter” as used herein generally refers to medical devices that can be inserted in the body to treat diseases or perform a surgical procedure.
[00174] The term“connected” as used herein generally refers to pieces which are physically joined or linked together.
[00175] The term“coupled” as used herein generally refers to pieces which may be used operatively with each other, or physically joined or physically linked together directly, with or without one or more intervening members.
[00176] The term“directly” as used herein generally refers to one structure in physical contact with another structure, or, when used in reference to a procedure, means that one process effects another process or structure without the involvement of an intermediate step or component.
[00177] The term“stylet” as used herein generally refers to a probe, typically a slender probe. Intraventricular Access Device:
[00178] CSF sampling is inherently important both from a safety and efficacy perspective. From a safety perspective, the ability to both monitor potential infection as well as drug levels is important. From an efficacy perspective, understanding drug levels are important to monitor drug treatments. Accordingly, there is a desire to provide a device for the direct administration
of drug therapies to the brain through an intraventricular access device that allows for access to the CSF through a port located just beneath the scalp of a patient. The system can furthermore be attached to an implantable drug pump or an external syringe or equivalent type pump.
[00179] In some embodiments, an intraventricular access device may provide an implantable drug delivery device that facilitates drug administration as well as sampling in the brain of a human patient. The access for drug sampling may occur at a separate location than the drug infusion to minimize cross contamination. Drug sampling may be performed with a sharp needle and as such the intraventricular access device includes protections such that the needle for sampling will not penetrate the infusion catheter. With such design safeguards, mixing and inaccuracies may be avoided. Both infusion and sampling access points within the brain are done relatively close to each other as such sampling and infusion may be accomplished in such a way to minimize cross contamination. The drug delivery device is adapted for implantation into a human subject and drug delivery to the CSF. The drug delivery device includes a support structure that may be accessed via skin puncture to sample the CSF.
[00180] In some embodiments, a device may include an intraventricular access device 100. FIG. 1 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device 100, specifically a catheter design with a concentric dual lumen design. Infusion and sampling ports are implanted in one of the lateral ventricles 200 of a subject’s brain 300. The infusion port (outer lumen) is connected to an implanted pump. The intraventricular access device may include a catheter 110 and a container 120. In some embodiments, the catheter may include an aspiration lumen 110a and an infusion lumen 110b. A distal end of the catheter (e.g., 5-6 cm length) may be positionable, during use, in a subject’s brain. In some embodiments, the container 120 may be coupled to a proximal end of the aspiration lumen 110a. The proximal end of the aspiration lumen may be in fluid communication with the container. In some embodiments, the device inhibits cross contamination between a first fluid in the aspiration lumen and a second fluid in the infusion lumen. Cross contamination may be inhibited by using two separate lumens for sampling and infusion.
[00181] Cross contamination may be inhibited using other systems and/or methods. In some embodiments, the container 120 may include a barrier 130 positioned between a proximal opening of the aspiration lumen and at least a portion of the infusion lumen adjacent to and/or associated with the container. The barrier may inhibit penetration of a surgical instrument (e.g., hypodermic needle). For example, a needle may be used to collect a sample from the container conveyed up through the aspiration lumen and the barrier may inhibit accidental puncture of the infusion lumen by the needle during the procedure. FIG.2 depicts a diagram of a cross sectional
view of an embodiment of a portion of an intraventricular access device 100, specifically a side by side dual lumen design including an infusion pathway distinct from the infusion catheter coming from the pump which is shielded from the sampling port from being penetrated by a hypodermic or other needle during aspiration.
[00182] In some embodiments, the infusion side or segment and the infusion pathway will be covered by a barrier (e.g., metal or other hard plastic material (e.g. PEEK)) to limit the ability of a needle to penetrate and potentially cause a fenestration between the two sides. The top portion on the container may be a silicon-type material that can be punctured by a needle, but which re- seals after the needle is withdrawn. In some embodiments, the container may have guide members 180 (e.g., be a cone-shape) so that the needle will be guided to the location of the sampling lumen 110a.
[00183] In some embodiments, the container may include a marker to indicate a position of the barrier. In some embodiments, one or more portions of the intraventricular access device 100 may include a marker of some kind including, but not limited to, any portion of the device positionable within the subject. The device may include multiple individually distinguishable markers. Markers may be used to assess a position of one or more portions of the device during and/or after implantation in a subject. A portion of the implant may include none, one or multiple markers. Markers may provide radiographic opacity. Markers may be biocompatible. Markers may be of any size or shape. In some embodiments, a system may have multiple markers with different shapes in order to more easily identify different portions of the system and/or an orientation of one or more portions of the device. In some embodiments, one or more markers may be formed from gold or tantalum.
[00184] The intraventricular access device may be designed to operate as part of a drug delivery system. The system includes a catheter that has distal openings in the CSF. The proximal side of the catheter is connected to a modified reservoir or container that may be accessed using, for example, a standard needle to draw CSF fluid from the distal end of the catheter to sample the CSF. In some embodiments, the infusion lumen may be coupled to a pump positioned externally or internally relative to the subject. For example, the container may contain a pathway for drug infusion and is connectable to a catheter which may connect to an implantable, programmable, refillable, drug pump. The pump may be implanted in the abdominal region of a patient. FIG. 3 depicts a diagram of a cross sectional view of an embodiment of an intraventricular access device 100 implanted with the sampling and infusion ports 110a-b located in one of the lateral ventricles 200. The infusion and sampling catheter in the brain is connected to a container 120 which is in turn connected to an implantable pump 140
(e.g., via an extension of the infusion lumen or an additional lumen 110c coupled to the infusion lumen) that is located, for example, in the abdomen. In some embodiments, a drug pump may be connected to an external pump 150 in addition to or in the alternative to an implantable pump. FIG.4 depicts a diagram of a cross sectional view of an embodiment of an intraventricular access device 100 implanted with the sampling and infusion ports 110a-b located in one of the lateral ventricles 200. The infusion and sampling catheter in the brain is connected to a container 120 which is in turn connected to an external pump 150 (e.g., a syringe pump via an extension of the infusion lumen or an additional lumen 110c coupled to the infusion lumen).
[00185] In some embodiments, implantable drug pumps such as the Synchromed® (Medtronic) or Prometra® (Flowonix) (or IP 2000V (Tricumed) or Siromedes (Tricumed)) that may be used for local and continuous infusion of drug therapies. These drug pumps are currently indicated for intrathecal drug delivery and have 20-40 mL refillable reservoirs; Tricumed reservoirs can go as high as 100 mL. They are indicated for the treatment of chronic, intractable pain, severe spasticity, and cancer. Alternatively, an external syringe type pump can be utilized. Syringe type pumps can include a pump like a Baxter 150XL.
[00186] Medications which may be introduced using the herein described system are not limited. In some embodiments, Morphine and Baclofen are both drugs that could be used as well as chemotherapies and other drugs for treatment of chronic and nonchronic diseases of the brain.
[00187] In some embodiments, aspiration lumen 110a may function as a sampling portal for obtaining a sample of a subject’s fluid. FIG. 5 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device 100, specifically a side by side dual lumen design. The infusion and sampling ports are implanted in one of the lateral ventricles. A container 120 fluidly coupled to at least the infusion lumen 110a may allow either directly inject drugs into the ventricles, or to sample CSF from the patient using an external syringe 160 (or an external pump 150).
[00188] In some embodiments, in the access device 100 the lumens 110 are tunneled up to the cisterna magna along the spine. FIG. 6 depicts a diagram of a cross sectional view of an embodiment of an access device 100 implanted with the sampling and infusion ports located in the cisterna magna. The infusion and sampling catheter in the brain is connected to a container 120 which is in turn connected to an implantable pump 140 that is located in the abdomen. The lumens 110 inserted into a spinal canal and tunneled (e.g., using a guidewire). In some embodiments, the container 120 (e.g., sampling reservoir) would either sit above the occipital bone, or the muscle layer of the lumbar spine or adjacent to the pump (e.g., in the abdomen or over the back). As described herein with other embodiments the device 100 may be coupled,
during use, to an internal or an external pump. In the current embodiment, features described herein to prevent cross contamination (e.g., a barrier) may be utilized. In the current embodiment, features described herein may be utilized including wherein the ends of the lumens being separated by a distance (e.g., 5mm to 1cm). The container (e.g., sampling reservoir) may separate from the double lumens so that the lumens are joined but the container has been separated from the joint lumens. For example, a T-shaped separation may be used in the tubing with one pathway from the T moving towards an aspiration reservoir and one pathway towards the infusion system. A T coupling 115 may be used in other embodiments disclosed herein. An installation stylet as described herein may be temporarily positioned in the infusion lumen or the aspiration lumen during placement in a subject. The device may be positioned using neuroimaging or other forms of intraoperative detection. Markers (e.g., metal portions of the device) may be used for neuroimaging (e.g., CT or MRI). Markers (e.g., a magnetic piece) may be used for intraoperative detection.
[00189] In some embodiments, installing the access device 100 may include positioning the lumens in a burr hole above the cerebellum on the left or right side. FIG. 6 depicts a diagram of a cross sectional view of an embodiment of an access device 100 implanted with the sampling and infusion ports located adjacent, behind or over the cerebellum 208. The infusion and sampling catheter in the brain is connected to a container 120 which is in turn connected to an implantable pump that is located in the abdomen. In some embodiments, a small microinsertion device may be used to position the lumens of the device through a small opening of less than one centimeter such that the lumens go through the burr hole opening. The inserted lumens may be flat or shaped like a tubing with two different pathways in it. The infusion pathway may infuse durally towards the dura or towards the brainstem or medial or lateral. The aspiration pathway may positioned in an opposing direction to the infusion lumen, specifically such that the opening of the aspiration lumen is directed in an opposing direction to the opening of the infusion lumen. In some embodiments, the openings may be facing the same direction.
[00190] The pathway of placing the device may be determined by a CT scan or an MRI scan preoperatively. Scans may depict the subarachnoid cisterns and placement of the catheter in the cerebellum. The targets could be any of the CSF subarachnoid cisterns including the cisterna magna, supracerebellar cisterns, CPA cistern or anterior to the brain stem cisterns. In some embodiments, a T-shaped separation 115 of the tubing as described herein may include one pathway directed towards an aspiration reservoir and one pathway directed towards an infusion system. In some embodiments, a stylet as described herein may be placed in the infusion lumen
(or the aspiration lumen) when positioning the device in the subject. This same approach could be used to position the device over the sylvian fissure or interhemisphernic cistern.
[00191] Elements in common to both a supracerebellar device and a hemisphere design include positioning the lumens through a small opening. Other common elements may include using preoperative imaging as a positioning guide and potentially using intra operative imaging as a positioning guide using either magnetic pieces in the device to see location and shape or using intraoperative MRI or intraoperative CT scan during positioning of the device. Common elements may include having a shape so that it would be anchored to the skull outside the cranium, and/or a stylet to guide passageway. For example, the container may include exterior adhesive means for coupling the container to an exterior surface of the cranium.
[00192] In some embodiments, the aspiration lumen and the infusion lumen are different lengths when positioned, during use, in the subject’s brain such that a distal end of the aspiration lumen and a distal end of the infusion lumen are positioned a distance away from one another. FIG. 7 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device 100, specifically a side by side dual lumen design. The infusion and sampling ports 110 are implanted in one of the lateral ventricles 200. The infusion port (110b) is connected to an implanted pump located near the abdomen. Positioning the distal ends of the aspiration and infusion lumens a distance away from one another may inhibit cross contamination of fluids.
[00193] The aspiration and infusion lumens may have different physical relationships relative to one another. FIGS.8A-C depict diagrams of a cross sectional view of several embodiments of a various dual lumen catheters 110 that may be used for the device described herein. In some embodiments, at least a portion of the infusion lumen is positioned in the aspiration lumen or at least a portion of the aspiration lumen is positioned in the infusion lumen (e.g., as depicted in FIGS. 1 and 8A). In some embodiments, the aspiration lumen and the infusion lumen may include a single lumen divided into two different lumens with a wall or divider (e.g., as depicted in FIG. 8B). In some embodiments, the aspiration lumen and the infusion lumen may include two different lumens positioned adjacent one another (e.g., as depicted in FIGS.5 and 8C).
[00194] In some embodiments, a distal end of the aspiration lumen comprises a first opening and a distal end of the infusion lumen comprises a second opening. The first opening and the second opening may be directed in a substantially opposing directions (e.g., at least orthogonally relative to one another) to inhibit cross contamination of fluids. The openings may be directed away from one another by bending (e.g., during fabrication and/or implantation) at least a portion of at least one of the distal ends of the aspiration and/or infusion lumen.
[00195] In some embodiments, a distal end of the aspiration lumen and/or the infusion lumen comprises at least one opening or a plurality of openings. In some embodiments, a distal end of the aspiration lumen and/or the infusion lumen comprises at least one opening which is inhibited from opening except when pressure is applied to the opening. FIG.9 depicts a diagram of a cross sectional view of an embodiment of a portion of an intraventricular access device 100, specifically a side by side dual lumen design with multiple flow holes 170 in the infusion catheter 110b. The flow holes may be open or may each consist of small“slits” that open when drug is infused (when there is positive pressure) and close when drug is not infused. This may be accomplished using a number of different methods. For example the opening may include a slit cut into a substantially resilient materials which flexes when under pressure but returns to an original shape after the pressure subsides (the original shape being a substantially closed slit in the lumen). The opening may include a more traditional opening closed off with a hinged cover (e.g., the hinge may include a resilient material as described herein since traditional mechanical hinges may be difficult to manufacture at the current dimensions).
[00196] In some embodiments, at least a portion of the container is formed from material that is penetrable by a needle and substantially reseals after extraction of the needle. In some embodiments, specialized needles may be employed that allow resealing and multiple penetrations when cerebrospinal fluid is aspirated. Specialized needles may include non-coring needles. For example a small non-coring butterfly needle may be used to (e.g., 23 or 25 gauge connected to a three-way tap) access the reservoir and collect a small amount of CSF.
[00197] The portion of the container may be on a proximal portion at least in a relation to the aspiration lumen such that the portion is facing away from the subject and therefore accessible. At least a portion or all of the container may be positioned subcutaneously in the subject (e.g., between a subject’s skull and skin). The resealable portion of the container may be exposed through the skin of the patient or be positioned beneath the skin. The resealable portion of the container may be formed from silicon. The reasealable portion may include an opening with a recloseable cap or stopper. The resealable portion may be replaceable after implantation.
[00198] Up to 25% of brain catheters fail due to clotting or tissues growing into the catheter holes. Thus, there is a need for a new type of catheter to limit tissue adherence as well as the risk of infection. Fibrous adhesions may bind the intrabrain portion of the infusion system to the proximate choroid plexus. Gentle rotation may free the catheter from the choroid plexus. If the catheter is stuck to the choroid plexus and is forcefully removed, there may be intraventricular hemorrhage. Thus, there exists a need to develop a catheter with an outer coating that also limits adherence and in-growth of tissue, particularly from the choroid plexus. In some embodiments,
at least portions of the device are formed from and/or coated in biocompatible materials which inhibit cell adhesion. In some embodiments, biocompatible materials such as Pebax, HDPE, LDPE, PTFE (polytetrafluoroethylene), ePTFE (expanded polytetrafluoroethylene), and polyimide may be used to inhibit cell adhesion. For example, as regards ePTFE independent experimental and clinical studies have demonstrated that the tight microstructure of the ePTFE surface of GORE PRECLUDE® PDX Dura Substitute is effective at minimizing tissue attachment. With an average porosity of less than one micron, the microstructure prevents penetration by fibroblasts and other mesenchymal cells and thus minimizes dense fibrous ingrowth.
[00199] In some embodiments, mechanical smoothing may be used on portions to limit micro locations for adhesions and the shapes of the holes can be made slit-like or very small via manufacturing techniques such as laser micromachining.
[00200] In some embodiments, at least portions of the device are formed from and/or coated in biocompatible materials comprising an antimicrobial. Antibacterial coatings composed of either silver or antibiotic impregnation similar to the catheters currently on the market. Portions of the device may be impregnated with antibiotics (e.g., rifampicin and clindamycin).
[00201] Choice of materials may be important as regards manufacture of devices described herein. For example, granuloma associated with morphine spine infusion has been of concern. Being careful of the molecule (morphine appears to be a major culprit), making sure the device materials in the infusion system are produced using high quality products to avoid impurities, and/or placing the catheter in areas of high CSF flow relative the flow in the spinal areas, may result in the risk for granulomas being minimized.
[00202] The system can either be modular or in one continuous system. The catheter is in one system or can be in two pieces from the container. The container may be either preassembled with a top or with the top that can be added separately. If the top is in place, a modified spinal needle or another rigid type device is necessary for controlled placement. If it is in two pieces a standard cannula can be in place that is not sharp.
[00203] In some embodiments, during implantation general procedures of import may include long tunneling, antibiotic cuffs at entry sites, using filters, avoiding flushing, maintaining sterile techniques, sometimes using injected antibiotics and/or educating patients on self-care.
[00204] FIGS. 9-11 depicts a diagram of a top view of an embodiment of a portion of an implanted intraventricular access device detailing an implantation method. In some embodiments, insertion of devices described herein may include inserting extraventricular drains at Kocher’s point 190, to have the catheter tip in the frontal horn of the lateral ventricle. The
catheter may be inserted on the right side of the brain via a frontal incision 192. The burr hole 194 may be created using a ventriculostomy procedure, sterile techniques, verification of catheter placement, tunneling 196 (including one or more incisions 198) and connections to drug pump. The catheter is designed to facilitate ease of use, accuracy, safety and durability of the procedure and the implant.
[00205] In some embodiments, a method includes aspirating and infusing at least a portion of a subject’s brain fluid. The method may include penetrating an upper portion of a container of a device using a needle. The method may include aspirating a first fluid from a first portion of a subject’s brain fluid through an aspiration lumen coupled to the container and using the needle. The method may include infusing a second fluid into a second portion of a subject’s brain fluid through an infusion lumen coupled to the container and the aspiration lumen. The method may include inhibiting penetration of the infusion lumen by the needle.
[00206] In some embodiments, the method may include infusing the second fluid using a pump coupled to the infusion lumen. The pump may be positioned externally or internally (e.g., subcutaneously, in a body cavity, etc.) relative to the subject. The method may include positioning at least a portion of the infusion lumen coupled to a pump subcutaneously.
[00207] In some embodiments, the method may include positioning at least a portion of the aspiration and/or the infusion lumen in the subject’s brain using a substantially inflexible stylet. The stylet may be positioned in the aspiration lumen by running the stylet through the container. FIGS.8D-F depict a stylet 115 positioned in one or more lumens during installation of the device described herein. The stylet 115 may be used to insert the device in a subject’s brain fluid. The stylet may be positioned in the aspiration and/or the infusion lumen. The stylet may be more than about 7 cms in length. The stylet may penetrate at least ½ the length of the aspiration catheter within the brain during use. If the stylet is positioned in both lumens, either two stylets may be used or one stylet with a split end may be used. The method may include observing at least a portion of the device during implantation using neuroimaging (e.g., MRI). Towards that end many if not all of the materials used to form the device may be compatible with common neuroimaging devices such as MRI.
[00208] In some embodiments, a stylet may be used to assist insertion of the device by positioning the stylet in the aspiration lumen before the reservoir or through the reservoir for aspiration. In some embodiments, a stylet may be used to assist insertion of the device by positioning the stylet in the infusion lumen before connection to an implantable or external pump.
[00209] In some embodiments, the method may include inhibiting penetration of the infusion lumen by the needle using a barrier positioned between a proximal opening of the aspiration lumen and at least a portion of the infusion lumen adjacent to and/or associated with the container. The barrier may inhibit cross contamination in general between the lumens. In some embodiments, the barrier may be formed from the same materials as the container but may consist of a greater thickness (this may tactically alert a care giver inserting a needle that they are unknowingly inserting the needle to far into the container and close to penetrating the barrier. In some embodiments, the barrier may be formed from a different material than the container. The barrier may be formed from a substantially rigid, rigid, or inflexible material such as PTFE or a metal or metal composite.
[00210] In some embodiments, the method may include inhibiting at least one opening at a distal end of the aspiration lumen and/or the infusion lumen from allowing fluids through the opening except when at least predetermined amount of pressure is applied to the opening in a first direction. The method may include inhibiting the opening from allowing fluids through the opening in a second direction even under pressure.
[00211] In this patent, certain U.S. patents, U.S. patent applications, and other materials (e.g., articles) have been incorporated by reference. The text of such U.S. patents, U.S. patent applications, and other materials is, however, only incorporated by reference to the extent that no conflict exists between such text and the other statements and drawings set forth herein. In the event of such conflict, then any such conflicting text in such incorporated by reference U.S. patents, U.S. patent applications, and other materials is specifically not incorporated by reference in this patent.
[00212] 1. Method: Steps in inserting this specialized catheter: Preparation: Standard bur hole, Dura will be coagulated and pia arachnoid opened. Assembly: Step one is aspirate csf, step two is flush infusion port, step three is check tubing from the pump and make sure there is a fluid head at top of tubing, step four connect infusion tubing to the housing, step five put a ligature, sow it up.
[00213] 2. Stylet– to guide input
[00214] a. Stylet will go through the central position of the longer catheter (
[00215] b. Aspiration catheter is closed at the tip in the brain because of the stylet
[00216] c. Stylet position in sampling catheter must be such that putting in the stylet cannot poke the infusion catheter along its course by either:
[00217] i. central hub metal hub to extend a few mm downwards to guide stylet in right direction downward and away from poking infusion catheter
[00218] ii. metal cover on infusion catheter pathway in the housing to avoid poking outward into the infusion catheter
[00219] iii. positioning will also avoid it so that infusion pathway is around the side
[00220] b. Housing has a pathway for the infusion catheter from the side and out the bottom central, on the side infusion pathway will snap onto the infusion catheter which can be modified for all infusion catheters
[00221] d. Housing will be v shaped on inside for CSF collection
[00222]
[00223] i. Infusion port will have a to have a small 2 ml syringe with small tubing which can hook and flush it out the infusion tubing first to confirm debris has not clogged this tubing at time of placement of catheter.
[00224] j. Volume for aspiration in the infusion can be 1.5– 2.5 mls of the V area in the housing for CSF aspiration and we want the volume small certainly don’t want it 5 mls like an ommaya.
[00225] For Catheter into brain
[00226] a. Infusion - 3 holes over 3 - 5m
[00227] d. longer catheter with stylet closed at the end so not poke brain or cause bleeding
[00228] e. aspiration has the stylet piece
[00229] f. aspiration 3 - 5 mm long space with multiple holes
[00230] g. Offset between aspiration and infusion at least 2 mm and positioned in other direction if needed
[00231] h. total length of holes for both infusion and aspiration from tip no longer than 25 mm
[00232] i. the infusion catheter internal diameter can be a smaller width than the aspiration width
[00233] j. Two catheters will be coated toether on outside– shape is like a larger catheter in the middle which is the aspiration and a smaller one next to it which is than overlayed with a rubber so that it is one piece and one length when inserted.
[00234] a. Ease of removal– snap off of infusion catheter which comes from either the internalized or externalize pump before it goes into housing from housing so the housing can be disconnected without a surgical procedure and then several days later connected to an internalized pump,
[00235] Further modifications and alternative embodiments of various aspects of the invention will be apparent to those skilled in the art in view of this description. Accordingly, this
description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as the presently preferred embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes may be reversed, and certain features of the invention may be utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description of the invention. Changes may be made in the elements described herein without departing from the spirit and scope of the invention as described in the following claims.
Claims
WHAT IS CLAIMED IS: 1. A use of an intraventricular access device for infusing a liquid formulation of a drug into a patient’s brain the device, comprising:
a catheter including an aspiration lumen and an infusion lumen, wherein a distal end of the catheter is positionable, during use, in the patient’s brain fluid; and
a container coupled to a proximal end of the aspiration lumen, wherein the proximal end of the aspiration lumen is in fluid communication with the container;
wherein a proximal end of the infusion lumen is coupled, during use, to an external or implantable pump and the pump infuses the liquid formulation comprising a drug through the infusion lumen and into the patient’s brain at a rate of 5ml or less per day to thereby treat a neurological disorder.
2. The use of claim 1, wherein the rate is 4ml per day or less.
3. The use of claim 1, wherein the rate is 1ml per day ± 50%.
4. The use of claim 1, wherein the infusion rate is less than 3ml per day and greater than 0.1ml per day with drug in the formulation at a concentration in a range of from 1 mg/ml to 500mg/ml.
5. The use of any of claims 1-4 wherein the infusing is continued for a period of one month or more and the drug is valproic acid or a pharmaceutically acceptable salt or base thereof.
6. The use of any of claims 1-5, wherein the infusion rate is substantially constant over one month more and the drug is valproic acid or a pharmaceutically acceptable salt or base thereof.
7. The use of any one of claims 1-6, wherein the use further comprises:
aspirating a sample of fluid from the subject’s brain, that sample having a volume of 3ml or less;
determining drug level in the sample; and
adjusting the rate of infusion of the liquid formulation based on the determined drug level in the sample fluid.
8. The use of any one of claims 1-7, wherein the use further comprises:
selecting a patient suffering from epilepsy which patient is non-responsive to treatment with oral anti-epileptic drugs.
9. The use of any one of claims 1-8 wherein the use further comprises:
selecting patient with a severe form of epilepsy in danger of brain damage or death.
10. The use of any one of claims 1-9, wherein the patient has been diagnosed with a neurological disease selected from the group consisting of:
epilepsy, post-traumatic stress disorder (PTSD) bipolar disorder, brain cancer, Glioblastoma, Alzheimer’s diseases, Parkinson’s diseases, closed head injury, stroke, multiple sclerosis, depression, schizophrenia, headache, pain disorders and anxiety.
11. The use of any one of claims 1-9, wherein the neurological disorder is selected from the group consisting of epilepsy, post-traumatic stress disorder (PTSD) bipolar disorder, brain cancer, Glioblastoma, Alzheimer’s disease, Parkinson’s disease, closed head injury, stroke, multiple sclerosis, depression, schizophrenia, headache, pain disorders and anxiety; and
wherein the patient has been determined as non-responsive to treatment with oral medication.
12. The use of any one of claims 1-11, wherein the drug is selected from the group consisting of valproic acid, benzodiazepine, lithium, irinotecan, Beta amyloid secretase inhibitors, tau protein antibodies, glial derived neurotrophic factor (GDNF), Glatiramer acetate, beta interferences, MAOi monoamine oxidase, TCA tricyclic antidepressants, clozapine, clozanezapam, and isocarboxazid.
13. The used of any one of claims 1-12, wherein the aspiration lumen is used only for sampling of the subject’s brain fluid and is positioned such that a distal end of the aspiration lumen and a distal end of the infusion lumen are positioned away from one another.
14. The use of claim 13, wherein the rate is 1ml per day ± 50% and drug is in the drug solution at a concentration in a range of 2 mg/ml to 500 mg/ml, ±20%.
15. The use of any one of claims 1-14, wherein the drug is an anti-epileptic drug selected from the group consisting of:
Carbatrol, Epitol, Equetro, Tegretol (carbamazepine);
Gabitril (tiagabine);
Keppra (levetiracetam);
Lamictal (lamotrigine);
Lyrica (pregabalin);
Fenfluramine;
Gralise, Horizant, Neurontin, Gabarone (gabapentin);
Dilantin, Prompt, Di-Phen, Epanutin, Phenytek (phenytoin); Topamax, Qudexy XR, Trokendi XR, Topiragen (topiramate); Trileptal, Oxtellar (oxcarbazepine);
Depacon, Depakene, Depakote, Stavzor (valproate, valproic acid); Zonegran (zonisamide);
Fycompa (perampanel);
Aptiom (eslicarbazepine acetate);
Vimpat (lacosamide);
Sabril (vigabatrin);
Banzel, Inovelon (rufinamide);
Cerebyx (fosphenytoin);
Zarontin (ethosuximide);
Solfoton, Luminal (phenobarbital);
Valium, Diastat (diazepam);
Ativan (lorazepam);
Lonopin, Klonopin (clonazepam);
Frisium, Onfi (clobazam);
Potiga (ezogabine);
Felbatol (felbamate);
Mysoline (primidone);
Acetazolamide;
Brivaracetam;
Clorazepate;
Ethotoin;
Mephenytoin;
Methsuximide;
Trimethadione; and
Bumetanide;
Adenosine; and
Adenosine a1 receptor agonists;
wherein the patient has been determined as non-responsive to treatment with oral medication.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/252,113 | 2019-01-18 | ||
US16/252,113 US20190151239A1 (en) | 2016-07-28 | 2019-01-18 | Infusing drug solution directly into brain fluid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020149993A1 true WO2020149993A1 (en) | 2020-07-23 |
Family
ID=69188000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/068592 WO2020149993A1 (en) | 2019-01-18 | 2019-12-26 | Infusing drug solution directly into brain fluid |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020149993A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220133989A1 (en) * | 2020-10-29 | 2022-05-05 | Medtronic, Inc. | Cyclic intrathecal drug delivery system and biomarker monitoring |
WO2023199125A1 (en) * | 2022-04-15 | 2023-10-19 | Mentor Worldwide Llc | Systems, devices and methods for aspirating fluids that collect around tissue expanders that are implanted in breast tissue |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050137578A1 (en) * | 2002-12-23 | 2005-06-23 | Medtronic, Inc. | Catheters incorporating valves and permeable membranes |
US20060160899A1 (en) * | 2003-10-23 | 2006-07-20 | Medtronic, Inc. | Intrathecal Gabapentin for Treatment of Epilepsy |
US8808234B2 (en) | 2010-03-10 | 2014-08-19 | The Cleveland Clinic Foundation | Catheter assembly |
US8979822B2 (en) | 2011-06-06 | 2015-03-17 | The Cleveland Clinic Foundation | Catheter assembly |
WO2018023041A1 (en) * | 2016-07-28 | 2018-02-01 | Cerebral Therapeutics | Implantable intraventricular sampling and infusion access device |
WO2019084038A1 (en) * | 2017-10-23 | 2019-05-02 | Cerebral Therapeutics LLC | High concentration valproic acid solutions for treating neurological disorders |
-
2019
- 2019-12-26 WO PCT/US2019/068592 patent/WO2020149993A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050137578A1 (en) * | 2002-12-23 | 2005-06-23 | Medtronic, Inc. | Catheters incorporating valves and permeable membranes |
US20060160899A1 (en) * | 2003-10-23 | 2006-07-20 | Medtronic, Inc. | Intrathecal Gabapentin for Treatment of Epilepsy |
US8808234B2 (en) | 2010-03-10 | 2014-08-19 | The Cleveland Clinic Foundation | Catheter assembly |
US8979822B2 (en) | 2011-06-06 | 2015-03-17 | The Cleveland Clinic Foundation | Catheter assembly |
WO2018023041A1 (en) * | 2016-07-28 | 2018-02-01 | Cerebral Therapeutics | Implantable intraventricular sampling and infusion access device |
WO2019084038A1 (en) * | 2017-10-23 | 2019-05-02 | Cerebral Therapeutics LLC | High concentration valproic acid solutions for treating neurological disorders |
Non-Patent Citations (3)
Title |
---|
BARCIA J A ET AL: "Intraventricular and Intracerebral Delivery of Anti-epileptic Drugs in the Kindling Model", NEUROTHERAPEUTICS, ELSEVIER INC, US, vol. 6, no. 2, 1 April 2009 (2009-04-01), pages 337 - 343, XP026077718, ISSN: 1933-7213, [retrieved on 20090328], DOI: 10.1016/J.NURT.2009.01.015 * |
DAIEL J ABRAMS: "Feasibility of Delivery of Anti-Epilepsy Medications into the Cerebrospinal Fluid (10802)", NEUROMODULATION, vol. 19, no. 3, 10 December 2015 (2015-12-10), US, pages e107, XP055539243, ISSN: 1094-7159, DOI: 10.1111/ner.12428 * |
SERRALTA A ET AL: "Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model", EPILEPSY RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 70, no. 1, 1 July 2006 (2006-07-01), pages 15 - 26, XP027974202, ISSN: 0920-1211, [retrieved on 20060701] * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220133989A1 (en) * | 2020-10-29 | 2022-05-05 | Medtronic, Inc. | Cyclic intrathecal drug delivery system and biomarker monitoring |
US11744939B2 (en) * | 2020-10-29 | 2023-09-05 | Medtronic, Inc. | Cyclic intrathecal drug delivery system and biomarker monitoring |
WO2023199125A1 (en) * | 2022-04-15 | 2023-10-19 | Mentor Worldwide Llc | Systems, devices and methods for aspirating fluids that collect around tissue expanders that are implanted in breast tissue |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230091409A1 (en) | Implantable intraventricular sampling and infusion access device | |
US20220409530A1 (en) | Infusing drug solution directly into brain fluid | |
AU2020217365B2 (en) | Intraosseous infusion ports and methods of use | |
JP4604022B2 (en) | Portable device for the administration of fluids to tissues and tumors by a delivery-enhanced delivery method | |
EP0746381B1 (en) | Implantable access devices | |
US8529525B2 (en) | Implantable vascular access system | |
JP6113283B2 (en) | Fluid exchange catheter and method for removing obstruction of fluid exchange catheter | |
EP2042212B1 (en) | Catheter for reduced reflux in targeted tissue delivery of a therapeutic agent | |
US20030045866A1 (en) | Method for convection enhanced delivery catheter to treat brain and other tumors | |
US20060189959A1 (en) | High flow diffusion catheter | |
US9402974B2 (en) | Optimized intracranial catheters for convection-enhanced delivery of therapeutics | |
US20060184098A1 (en) | Subarachnoid spinal catheter for transporting cerebrospinal fluid | |
EP3532140B1 (en) | Multi-lumen indwelling catheter | |
WO2020149993A1 (en) | Infusing drug solution directly into brain fluid | |
US20230364326A1 (en) | Implantable medical device and system | |
WO2021071701A1 (en) | Subcutaneous infusion cannulas having a plurality of apertures for dosage distribution over a wide area of subcutaneous tissue | |
JP2019524253A (en) | Implantable medical device for local area injection | |
WO2007075912A2 (en) | A system and method of administering a therapeutic material to brain tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19842545 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19842545 Country of ref document: EP Kind code of ref document: A1 |